



UNIVERSITI PUTRA MALAYSIA

***INDUCTION OF APOPTOSIS AND THE SIGNALLING PATHWAYS
INVOLVED BY *Dillenia suffruticosa* DICHLOROMETHANE ROOT EXTRACT
IN MCF-7 AND MDA-MB-231 BREAST CANCER CELLS***

FOO JHI BIAU

IB 2015 19



**INDUCTION OF APOPTOSIS AND THE SIGNALLING PATHWAYS
INVOLVED BY *Dillenia suffruticosa* DICHLOROMETHANE ROOT EXTRACT
IN MCF-7 AND MDA-MB-231 BREAST CANCER CELLS**

By

FOO JHI BIAU

**Thesis Submitted to the School of Graduate Studies,
Universiti Putra Malaysia, in Fulfilment of the Requirements for the
Degree of Doctor of Philosophy**

April 2015

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirements for the degree of Doctor of Philosophy

INDUCTION OF APOPTOSIS AND THE SIGNALLING PATHWAYS INVOLVED BY *Dillenia suffruticosa* DICHLOROMETHANE ROOT EXTRACT IN MCF-7 AND MDA-MB-231 BREAST CANCER CELLS

By

FOO JHI BIAU

April 2015

Chairman : Latifah Saiful Yazan, PhD

Faculty : Institute of Bioscience

Dillenia suffruticosa has been used traditionally to treat cancerous growth. Previous study reported that dichloromethane extract of *D. suffruticosa* root (DCM-DS) was the most cytotoxic towards breast cancer cells. The present study investigated the mode of cell death and the signalling pathways involved in MCF-7 and MDA-MB-231 breast cancer cells treated with DCM-DS. DCM-DS was obtained by sequential solvent extraction. The cytotoxicity of DCM-DS was determined by using MTT assay. The mode of cell death was evaluated by using an inverted light microscope and Annexin-V/PI-flow cytometry analysis. Cell cycle analysis and measurement of intracellular reactive oxygen species (ROS) level were performed by using flow cytometry. The cells were co-treated with DCM-DS and antioxidants α -tocopherol or ascorbic acid to evaluate the involvement of ROS in the cytotoxicity of DCM-DS. Effect of DCM-DS on the expression of antioxidant, apoptotic, growth, survival genes and proteins were analysed by using GeXP-based multiplex system and Western blot, respectively. The compounds in DCM-DS were isolated by various chromatography techniques. The structure of the compounds was elucidated by using nuclear magnetic resonance analysis. DCM-DS was cytotoxic to the MCF-7 and MDA-MB-231 cells in a time- and dose-dependent manner. Cell cycle analysis revealed that DCM-DS induced G₀/G₁ and G₂/M phase cell cycle arrest in MCF-7 and MDA-MB-231 cells, respectively. DCM-DS induced apoptosis and oxidative stress in these two cell lines. Treatment with α -tocopherol reduced the cytotoxicity of DCM-DS at 50 μ g/mL in the cells, suggesting that DCM-DS induced lipid peroxidation to destroy the cancer cells. Therefore, DCM-DS can be employed as a pro-oxidant agent to treat breast cancer. The induction of apoptosis in MCF-7 and MDA-MB-231 cells by DCM-DS is possibly due to the activation of pro-apoptotic JNK1 and down-regulation of anti-apoptotic ERK1 and AKT1, which in turn down-regulates anti-apoptotic BCL-2 to increase the BAX/BCL-2 ratio to initiate the mitochondrial apoptotic pathway. The induction of cell cycle arrest in MCF-7 and MDA-MB-231 cells is possibly via p53/p21-dependent and p53-independent but p21-dependent pathway, respectively. A total of seven triterpene compounds were isolated. Betulinic acid (BA) appears to be the major and most cytotoxic compound in DCM-DS. Therefore, BA could be used as a mean for standardisation of herbal product from *D. suffruticosa*. In conclusion, the data suggest the potential application of DCM-DS in the treatment of breast cancer.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan ijazah Doktor Falsafah

**ARUHAN APOPTOSIS DAN LALUAN ISYARAT TERLIBAT OLEH
EKSTRAK DIKLOROMETANA AKAR *Dillenia suffruticosa* TERHADAP SEL
KANSER PAYUDARA MCF-7 DAN MDA-MB-231**

Oleh

FOO JHI BIAU

April 2015

Pengerusi : Latifah Saiful Yazan, PhD

Fakulti : Institut Biosains

Dillenia suffruticosa telah digunakan secara tradisional untuk merawat pertumbuhan kanser. Kajian terdahulu melaporkan bahawa ekstrak diklorometana dari akar *D. suffruticosa* (DCM-DS) adalah yang paling sitotoksik terhadap sel kanser payudara. Kajian ini menyiasat cara kematian sel dan laluan isyarat yang terlibat dalam sel kanser payudara MCF-7 dan MDA-MB-231 dirawat dengan DCM-DS. DCM-DS diperolehi melalui pengekstrakan berurutan pelarut. Sitotoksiti DCM-DS ditentukan oleh asai MTT. Cara kematian sel ditentukan dengan mikroskop keterbalikan dan analisis aliran sitometri dengan *Annexin-V/PI*. Analisis kitaran sel dan pengukuran paras spesies oksigen reaktif (ROS) intrasel dilaksanakan dengan aliran sitometri. Sel kanser tersebut dirawat dengan DCM-DS dan antioksidan α -tokoferol atau asid askorbik untuk menentukan penglibatan ROS dalam sitotoksiti DCM-DS. Kesan DCM-DS terhadap pengekspresan gen dan protein untuk antioksidan, apoptosis, pertumbuhan dan daya tahan hidup dianalisis dengan menggunakan sistem multipleks GeXP dan Western blot, masing-masing. Sebatian dalam DCM-DS diasingkan menggunakan pelbagai teknik kromatografi. Struktur sebatian dikenalpasti dengan resonans magnetik nuklear (NMR). DCM-DS adalah sitotoksik terhadap sel MCF-7 dan MDA-MB-231 secara bersandar pada masa dan dos. Analisis kitaran sel mendedahkan bahawa DCM-DS mengaruh penahanan fasa G_0/G_1 dan G_2/M kitaran sel terhadap sel MCF-7 dan MDA-MB-231, masing-masing. DCM-DS mengaruh apoptosis dan tekanan oksidatif terhadap kedua-dua jujukan sel tersebut, Rawatan dengan α -tokoferol mengurangkan sitotoksiti DCM-DS pada 50 $\mu\text{g}/\text{mL}$ dalam sel tersebut. Ini mencadangkan bahawa DCM-DS mengaruh pengoksidaan lipid untuk memusnahkan sel kanser tersebut. Justeru itu, DCM-DS boleh diguna sebagai agen pro-oksidan untuk merawat kanser payudara. Aruhan apoptosis dalam sel MCF-7 dan MDA-MB-231 oleh DCM-DS berkemungkinan disebabkan oleh pengaktifan JNK1 pro-apoptotik dan penurunan ERK1 dan AKT1 anti-apoptotik, seterusnya menurun BCL-2 anti-apoptotik dan meningkat nisbah BAX/BCL-2 untuk memulakan laluan apoptotik mitokondria. Penahanan kitaran sel dalam sel MCF-7 dan MDA-MB-231 dirawat DCM-DS berkemungkinan melalui laluan bergantung p53/p21 dan tidak bergantung p53 tetapi bergantung p21, masing-masing. Sejumlah tujuh sebatian triterpin telah diasingkan. Asid betulinic (BA) merupakan sebatian yang paling banyak dan paling sitotoksik dalam DCM-DS. Oleh itu, BA boleh digunakan untuk tujuan pemiawaian produk herba dari *D. suffruticosa*. Sebagai penutup, data mencadangkan potensi aplikasi DCM-DS dalam rawatan kanser payudara.

ACKNOWLEDGEMENT

“Rome was not built in a day” – so goes the famous saying, and the completion of a project of any scale would most definitely not be accomplished with the efforts of one individual alone. Therefore, I would like to take this opportunity to express my deepest gratitude to several individuals, who lent their support in various ways throughout the duration of my study.

First and foremost, I would like to express my deepest gratitude to my supervisor, Associate Professor Dr. Latifah Saiful Yazan for her valuable guidance, suggestions, encouragement and believing in my research capabilities throughout my project and preparation of the thesis.

I would like to extend my sincere gratitude to my co-supervisor, Professor Rasedee Abdullah and Associate Professor Dr. Cheah Yoke Kqueen for their support and valuable comments in making this research a success. Thank you for your kindness to help when I need it most.

Not to be forgotten to express my sincere thanks to Professor Dr. Johnson Stanslas, Dr. Mustapha Umar, Dr. Yeap Swee Keong, Professor Maznah Ismail, Associate Professor Dr. Intan Safinar Ismail and Dr. Cinzia Allegrucci for their generosity to assist throughout the study. The ideas and guidance are appreciated.

I am very grateful to all the science officers, assistants and technicians in Institute of Bioscience, Universiti Putra Malaysia, Mrs. Siti Muskinah, Ms. Norsharina, Mr. Kim Wei, Ms. Norhayati, Mr. Abidin, Mrs. Mastura, Ms. Siti Aisyah, Mrs. Lina, Mrs. Nancy, Mrs. Norhafiza, Ms. Normahfuzah, Dr. Tan Sheau Wei, Mrs. Tommini, Mrs. Norazalina, Mrs. Nooraini, Mrs. Norlela, Mr. Ahmad Termizi, Mrs. Ayuni, Mrs. Norhidayu and Mrs. Norul Ariffah; Staff of Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Mrs. Marsitah; Staff of Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Mrs. Shareena. Thank you very much for the guidance, kind assistance, informative description about the equipment, chemicals in the laboratory as well as the methods of handling and operating them.

Special thanks go to my group members and friends Mr. Hisyam, Mrs. Noreen, Mrs. Aina, Ms. Armania, Dr. How Chee Wun, Dr. Agustono Wibowo, Dr. Wei Keat, Mrs. Wan Nor Hafiza, Mrs. Kavitha, Dr. Yin Sim, Mr. Der Jiun, Mr. Wen Bin, Ms. Sarega, Ms. Yong Sze, Mrs. Hanisah, Ms. Sandy Mun Waei, Ms. Su Hua, Ms. Huan Yong and Ms. Mun Theng who have helped me directly and indirectly for the past three years. Thank you for the willingness to share knowledge with me. Learning from all of them is one of the most beautiful things happened in my life.

I would also like to acknowledge the financial support from Ministry of Education Malaysia for the Fundamental Research Grant Scheme (FRGS) and MyBrain15 (MyPhD) Scholarship, and Research University Grant (RUG6) for my study.

Last but not least, my deepest appreciation to my parents who have made me who I am today and my siblings who have always been there for me.

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirements for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Latifah Saiful Yazan, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Rasedee Abdullah, PhD

Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(member)

Cheah Yoke Kqueen, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced; this thesis has not been submitted previously or concurrently for any other degree at any institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by university Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/ fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _____ Date: 10 April 2015

Name and Matric No.: Foo Jhi Biau (GS32879)

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature : _____
Name of Chairman of
Supervisory
Committee : Assoc. Prof. Dr. Latifah Saiful Yazan

Signature : _____
Name of Chairman of
Supervisory
Committee : Prof. Dr. Rasedee Abdullah

Signature : _____
Name of Chairman of
Supervisory
Committee : Assoc. Prof. Dr. Cheah Yoke Kqueen

TABLE OF CONTENTS

	Page
ABSTRACT	v
ABSTRAK	vi
ACKNOWLEDGEMENTS	vii
APPROVAL	viii
DECLARATION	x
LIST OF TABLES	xvi
LIST OF FIGURES	xvii
LIST OF APPENDICES	xxi
LIST OF ABBREVIATIONS	xxii
CHAPTER	
1 INTRODUCTION	1
2 LITERATURE REVIEW	3
2.1 Breast cancer	3
2.1.1 Molecular classification	3
2.1.2 Staging	4
2.1.3 Epidemiology	5
2.1.4 Aetiology	5
2.1.5 Treatment	6
2.1.5.1 Chemotherapy for Luminal A and B subtype breast cancer	7
2.1.5.2 Chemotherapy for HER-2 positive breast cancer	7
2.1.5.3 Chemotherapy for triple-negative breast cancer	8
2.2 Breast cancer cell line	9
2.2.1 MCF-7	9
2.2.2 MDA-MB-231	10
2.3 Apoptosis and cancer	11
2.3.1 BCL-2 family	15
2.4 Signalling pathways of cancer	15
2.4.1 Mitogen-activated protein kinase pathway	15
2.4.1.1 ERK1/2	17
2.4.1.2 p38MAPK	17
2.4.1.3 JNK	19
2.4.2 AKT pathway	20
2.4.3 Nuclear factor kappa beta pathway	21
2.5 Cell cycle and cancer	23
2.6 Reactive oxygen species and cancer	24
2.7 Natural products	26
2.7.1 Commercialisation of herbal medicine	27
2.7.2 Standardisation of herbal product	28
2.7.3 Phytochemicals	30
2.7.3.1 Phenolic	30
2.7.3.2 Terpene	32
2.7.3.3 Alkaloid	32
2.7.3.4 Saponin	33

2.7.4	Isolation and elucidation of compounds	34
2.8	<i>Dillenia</i> species	35
2.8.1	<i>Dillenia suffruticosa</i>	39
2.8.2	Anticancer properties of betulinic acid	40
3	CYTOTOXICITY OF <i>Dillenia suffruticosa</i> DICHLOROMETHANE ROOT EXTRACT TOWARDS MCF-7 AND MDA-MB-231 CELLS	
3.1	Introduction	43
3.2	Materials and methods	44
3.2.1	Plant material	44
3.2.2	Chemicals	44
3.2.3	Preparation of plant extract	44
3.2.4	Cell culture	45
3.2.5	Determination of cytotoxicity	45
3.2.6	Morphological study	45
3.2.7	Cell cycle analysis	46
3.2.8	Determination of mode of cell death	46
3.2.9	Statistical analysis	46
3.3	Results	46
3.3.1	Cytotoxicity of DCM-DS towards MCF-7 and MDA-MB-231 cells	46
3.3.2	Morphological changes of MCF-7 and MDA-MB-231 cells treated with DCM-DS	49
3.3.3	Cell cycle arrest of MCF-7 and MDA-MB-231 cells by DCM-DS	53
3.3.4	Mode of cell death induced by DCM-DS in MCF-7 and MDA-MB-231 cells	57
3.4	Discussion	61
3.5	Conclusion	63
4	DETERMINATION OF REACTIVE OXYGEN SPECIES IN THE CYTOTOXICITY OF <i>Dillenia suffruticosa</i> DICHLOROMETHANE ROOT EXTRACT IN MCF-7 AND MDA-MB-231 CELLS	
4.1	Introduction	65
4.2	Materials and methods	66
4.2.1	Plant material	66
4.2.2	Chemicals	66
4.2.3	Preparation of plant extract	66
4.2.4	Cell culture	66
4.2.5	Measurement of the level of intracellular reactive oxygen species in MCF-7 and MDA-MB-231 cells treated with DCM-DS	66
4.2.6	Determination of the effect of antioxidants on the viability of MCF-7 and MDA-MB-231 cells treated with DCM-DS	67
4.2.7	Analysis of expression of antioxidant defence genes	67
4.2.7.1	RNA extraction	67
4.2.7.2	cDNA synthesis	67

	4.2.7.3	Polymerase chain reaction	68
	4.2.8	Statistical analysis	69
4.3		Results	69
	4.3.1	Level of intracellular reactive oxygen species in MCF-7 and MDA-MB-231 cells treated with DCM-DS	69
	4.3.2	Effect of antioxidants on the viability of MCF-7 and MDA-MB-231 cells treated with DCM-DS	70
	4.3.3	Expression level of the antioxidant genes of MCF-7 and MDA-MB-231 cells treated with DCM-DS	73
4.4		Discussion	74
4.5		Conclusion	76
5		ELUCIDATION OF SIGNALLING PATHWAYS INVOLVED IN APOPTOSIS INDUCED BY <i>Dillenia suffruticosa</i> DICHLOROMETHANE ROOT EXTRACT IN MCF-7 AND MDA-MB-231 CELLS	
	5.1	Introduction	77
	5.2	Materials and methods	78
	5.2.1	Plant material	78
	5.2.2	Chemicals	79
	5.2.3	Preparation of plant extract	79
	5.2.4	Cell culture	79
	5.2.5	Analysis of expression of apoptotic, growth and survival genes	79
	5.2.6	Analysis of expression of apoptotic, growth and survival proteins	81
	5.2.6.1	Protein extraction and separation	81
	5.2.6.2	Detection	82
	5.2.7	Statistical analysis	83
	5.3	Results	83
	5.3.1	Effect of DCM-DS on the expression of the apoptotic, growth and survival genes in MCF-7 and MDA-MB-231 cells	83
	5.3.2	Effect of DCM-DS on the expression of the apoptotic, growth and survival proteins in MCF-7 and MDA-MB-231 cells	86
	5.4	Discussion	94
	5.5	Conclusion	96
6		ISOLATION AND ELUCIDATION OF BIOACTIVE COMPOUNDS OF <i>Dillenia suffruticosa</i> DICHLOROMETHANE ROOT EXTRACT	
	6.1	Introduction	99
	6.2	Materials and methods	99
	6.2.1	Plant material	99
	6.2.2	Chemicals	99
	6.2.3	Preparation of plant extract	100
	6.2.4	Isolation of compounds	100

6.2.5	Elucidation of structure	101
6.2.6	Quantification of betulinic acid	101
6.2.7	Determination of cytotoxicity of the isolated compounds	102
6.2.8	Statistical analysis	102
6.3	Results	103
6.3.1	Isolated compounds from DCM-DS	103
6.3.2	Percentage of betulinic acid in DCM-DS	107
6.3.3	Cytotoxicity of the isolated compounds towards MCF-7 and MDA-MB-231 cells	109
6.4	Discussion	111
6.5	Conclusion	113
7	GENERAL DISCUSSION, CONCLUSION AND FUTURE WORKS	
7.1	General Discussion	115
7.2	Conclusion	118
7.3	Future works	118
	REFERENCES	119
	APPENDICES	155
	BIODATA OF STUDENT	173
	LIST OF PUBLICATION	174

LIST OF TABLES

Table		Page
2.1	Molecular classification of breast cancer subtype	3
2.2	Breast cancer TNM staging	4
2.3	Classification of chemotherapeutic drugs	6
2.4	Differences between apoptosis and necrosis	12
2.5	Frequently used spectroscopic techniques for structural determination and characterisation	35
2.6	Traditional use of <i>Dillenia</i> species	36
2.7	Pharmacological properties of different species of <i>Dillenia</i>	37
2.8	Compounds from genus <i>Dillenia</i> (family: Dilleniaceae)	38
3.1	Cytotoxicity of DCM-DS towards breast cancer and non-tumorigenic cell lines at different time point reflected by the IC ₅₀ values as determined by MTT assay	48
4.1	Antioxidant defence genes and their respective primers used in GeXP multiplex analysis	68
5.1	Apoptotic, growth and survival genes and their respective primers used in GeXP multiplex analysis	80
6.1	¹³ C- and ¹ H-NMR spectral data for Compound 3, 4 and 6	105
6.2	Retention time and area under curve of different concentration of standard BA obtained from HPLC	107
6.3	Cytotoxicity of the isolated compounds from DCM-DS and tamoxifen towards MCF-7 and MDA-MB-231 breast cancer cells at 72 hours reflected by the IC ₅₀ values as determined by MTT assay	110

LIST OF FIGURES

Figure		Page
2.1	Hallmarks of the apoptotic and necrotic cell death process	11
2.2	Extrinsic and intrinsic apoptotic pathways	14
2.3	The overall structures of MAPKs	16
2.4	MAPK signalling cascades that lead to the activation of MAPKs	16
2.5	Activation of p38MAPKs and Jun N-terminal kinases (JNKs) signalling pathways	18
2.6	AKT pathway in cancer	21
2.7	Activation of NF- κ B by either classical or alternative pathway	22
2.8	The cell cycle	23
2.9	Intracellular ROS generation	24
2.10	ROS and their role in the development of human cancer	25
2.11	Chromatograms of essential oils in <i>Cortex chinnamomi</i> from different producing areas	29
2.12	Phenol	30
2.13	Gallic acid	30
2.14	Catechin	31
2.15	Gallotannin	31
2.16	Isoprene (A) and betulinic acid (B)	32
2.17	Vincristine (A) and vinblastine (B)	33
2.18	Classification of saponins	33
2.19	Ginsenosides	34
2.20	<i>Dillenia suffruticosa</i>	39
3.1	Effect of DCM-DS on the viability of MCF-7 breast cancer cells as determined by MTT assay	47
3.2	Effect of DCM-DS on the viability of MDA-MB-231 breast cancer cells as determined by MTT assay	47

3.3	Effect of DCM-DS on the viability of non-tumorigenic MCF-10A cells as determined by MTT assay	48
3.4	The population of MCF-7 cells after treatment with DCM-DS as observed under an inverted light microscope (100×)	50
3.5	Close-up view of MCF-7 cells treated with DCM-DS at 48 hours (400×)	51
3.6	The population of MDA-MB-231 cells after treatment with DCM-DS as observed under an inverted light microscope (100×)	52
3.7	Close-up view of MDA-MB-231 cells treated with DCM-DS at 48 hours (400×)	53
3.8	Cell cycle profile of MCF-7 cells treated with DCM-DS	54
3.9	Cell cycle profile of MDA-MB-231 cells treated with DCM-DS	56
3.10	The percentage of MCF-7 and MDA-MB-231 cells treated with DCM-DS at different time point at the sub-G ₀ /G ₁ phase	57
3.11	The percentage of viable, early apoptotic and necrotic/secondary necrotic cells of untreated and DCM-DS-treated MCF-7 cells at different time point as determined by flow cytometry analysis using Annexin-V/PI	58
3.12	The percentage of viable, early apoptotic and necrotic/secondary necrotic cells of untreated and DCM-DS-treated MCF-7 cells at different time point as determined by flow cytometry analysis using Annexin-V/PI	59
3.13	The percentage of viable, early apoptotic and necrotic/secondary necrotic cells of untreated and DCM-DS-treated MDA-MB-231 cells at different time point as determined by flow cytometry analysis using Annexin-V/PI	60
3.14	The percentage of viable, early apoptotic and necrotic/secondary necrotic cells of untreated and DCM-DS-treated MDA-MB-231 cells at different time point as determined by flow cytometry analysis using Annexin-V/PI	61
4.1	The intracellular ROS level in MCF-7 cells treated with 50 μM H ₂ O ₂ or DCM-DS for 3 hours as determined by flow cytometry analysis using DCFH-DA assay	69
4.2	The intracellular ROS level in MDA-MB-231 cells treated with 50 μM H ₂ O ₂ or DCM-DS for 3 hours as determined by flow cytometry analysis using DCFH-DA assay	70

4.3	Viability of MCF-7 cells treated with DCM-DS and α -tocopherol or ascorbic acid for 24 (A) and 48 (B) hours	71
4.4	Viability of MDA-MB-231 cells treated with DCM-DS and α -tocopherol or ascorbic acid for 24 (A) and 48 (B) hours	72
4.5	Relative fold change of <i>SOD1</i> , <i>SOD2</i> and <i>CAT</i> expression level in DCM-DS-treated MCF-7 cells at 24 hours that was normalised against beta-actin and compared to the control	73
4.6	Relative fold change of <i>SOD1</i> , <i>SOD2</i> and <i>CAT</i> expression level in DCM-DS-treated MDA-MB-231 cells at 24 hours that was normalised against beta-actin and compared to the control	74
5.1	Relative fold change of the level of gene expression in DCM-DS-treated MCF-7 cells at 24 hours which was normalised against beta-actin and compared to the control	83
5.2	<i>BAX:BCL-2</i> ratio in DCM-DS-treated MCF-7 cells at 24 hours	84
5.3	Relative fold change of the level of gene expression in DCM-DS-treated MDA-MB-231 cells at 24 hours which was normalised against beta-actin and compared to the control	85
5.4	<i>BAX:BCL-2</i> ratio in DCM-DS-treated MDA-MB-231 cells at 24 hours	85
5.5	The expression of NF- κ B-p65, AKT1, ERK1, phospho-ERK1, JNK1 and phospho-JNK1 of DCM-DS-treated MCF-7 cells as determined by western blot analysis	87
5.6	The expression of p53, p21, BAX, BCL-2 and BAX/BCL-2 ratio of DCM-DS-treated MCF-7 cells as determined by western blot analysis	89
5.7	The expression of NF- κ B-p65, AKT1, ERK1, phospho-ERK1, JNK1 and phospho-JNK1 of DCM-DS-treated MDA-MB-231 cells as determined by western blot analysis	91
5.8	The expression of p21, BAX, BCL-2 and BAX/BCL-2 ratio of DCM-DS-treated MDA-MB-231 cells as determined by western blot analysis	93
5.9	Proposed mechanisms by which DCM-DS induced apoptosis in (A) MCF-7 and (B) MDA-MB-231 cells	97
6.1	Chemical structures of the isolated compounds from DCM-DS	103
6.2	Key $^1\text{H} \leftrightarrow ^{13}\text{C}$ HMBC correlations of Compound 3	106

6.3	Key $^1\text{H} \Leftrightarrow ^{13}\text{C}$ HMBC correlations of Compound 4	106
6.4	Key $^1\text{H} \Leftrightarrow ^{13}\text{C}$ HMBC correlations of Compound 6	107
6.5	HPLC profile of standard BA (1000 ppm)	108
6.6	HPLC profile of DCM-DS	108
6.7	Effect of Compound 1, 2, 4, 5 and 7 on the viability of MCF-7 breast cancer cells at 72 hours as determined by MTT assay	109
6.8	Effect of Compound 1, 2, 4, 5 and 7 on the viability of MDA-MB-231 breast cancer cells at 72 hours as determined by MTT assay	110



LIST OF APPENDICES

Appendix		Page
A	Experimental design	155
B	Intracellular ROS level in both MCF-7 and MDA-MB-231 cells treated with 50 μM H_2O_2 or DCM-DS for 3 hours as determined by flow cytometry analysis using DCFH-DA assay	156
C	TLC profile of the fractions of DCM-DS	157
D	Yield of the fractions of DCM-DS	158
E1	^{13}C -NMR profile of Compound 1	159
E2	^1H -NMR profile of Compound 1	160
F1	^{13}C -NMR profile of Compound 2	161
F2	^1H -NMR profile of Compound 2	162
G1	^{13}C -NMR profile of Compound 3	163
G2	^1H -NMR profile of Compound 3	164
H1	^{13}C -NMR profile of Compound 4	165
H2	^1H -NMR profile of Compound 4	166
I1	^{13}C -NMR profile of Compound 5	167
I2	^1H -NMR profile of Compound 5	168
J1	^{13}C -NMR profile of Compound 6	169
J2	^1H -NMR profile of Compound 6	170
K1	^{13}C -NMR profile of Compound 7	171
K2	^1H -NMR profile of Compound 7	172

LIST OF ABBREVIATIONS

ACTB	Beta-actin
AKT	Protein kinase B
APT	Attached proton test
BRCA1	Breast cancer 1
BRCA2	Breast cancer 2
CASP-3	Caspase-3
CAT	Catalase
CDK	Cyclin-dependent kinase
CK5/6	Cytokeratin 5/6
COSY	^1H - ^1H correlation spectroscopy
DCFH-DA	Dichlorodihydrofluorescein diacetate
FITC	Fluorescein isothiocyanate
EGF	Epidermal growth factor
EGFR	Epidermal growth factor receptor
ER	Oestrogen receptor
ERK	Extracellular signal-regulated kinase
HER2	Human epidermal growth factor receptor 2
HMBC	Heteronuclear multiple bond correlation
HSQC	Heteronuclear single quantum correlation
I κ B	Inhibitor of κ B
IKK	I κ B kinase
JNK	c-Jun N-terminal kinase
MAPK	Mitogen-activated protein kinase
MAPKK	MAPK kinase
MAPKKK	MAPKK kinase
MPTP	Mitochondrial permeability transition pores
NF- κ B	Nuclear factor-kappa B
NMR	Nuclear magnetic resonance
PARP	Poly (ADP-ribose) polymerase
PKC	Protein kinase C
PMSF	Phenylmethanesulfonyl fluoride
p38MAPK	p38 Mitogen-activated protein kinase
PR	Progesterone receptor
PS	Phosphatidylserine
SOD	Superoxide dismutase
TCM	Traditional Chinese medicine
T-DM1	Trastuzumab-DM1
TEY	Thr-Glu-Tyr
TGY	Thr-Gly-Tyr
TNBC	Triple-negative breast cancer
TNF	Tumour necrosis factor
TNM	Tumour, nodes and metastasis
TPY	Thr-Pro-Tyr
TRAIL	TNF-related apoptosis inducing ligand

CHAPTER 1

INTRODUCTION

Breast cancer is the leading cause of cancer death among females worldwide (Jemal *et al.*, 2011). There were approximately 1.7 million and 500,000 of new cases and deaths due to breast cancer, respectively, in 2012 worldwide. It is also estimated that one in eight women will develop breast cancer at some point in her lifetime (GLOBOCAN, 2012).

Breast cancer patients can be treated by chemotherapy, surgery and radiotherapy. Chemotherapy is the most common treatment that uses chemicals to kill or stop cancer cells from growing (Coates *et al.*, 2012). Nevertheless, the mortality rate of women with breast cancer is still relatively high due to recurrence and metastasis. The main cause for cancer recurrence is that the cancer cells have acquired resistance to the chemotherapy due to dysregulation of multiple genes and multiple cell signalling pathways, rendering the initial successful chemotherapy becomes ineffective (Holohan *et al.*, 2013; Curigliano, 2012; Marquette and Nabell, 2012; Dhillon *et al.*, 2011). In addition, chemotherapeutic drugs such as tamoxifen, trastuzumab, doxorubicin and cisplatin for the management of breast cancer (Silver *et al.*, 2010; Subik *et al.*, 2010; Adams *et al.*, 2006) have been reported to cause adverse effects such as increased incidence of endometrial cancer (Wysowski *et al.*, 2002), cardiotoxicity (Ichikawa *et al.*, 2014) (Cardinale *et al.*, 2010), and hematotoxicity (Pearcey *et al.*, 2002). Therefore, there is an urgent need to seek for other remedies for the management of breast cancer.

In contrast to the conventional single molecule-single target approach, being able to target two or more pathways at once or a few players in the same pathway would be a more effective therapy for cancer (Verpoorte, 2012; Dolgin, 2011). Thus, evidence-based herbal medicines might be one of the starts for these approaches. The mixture of active compounds in the herbal medicines may have synergistic effect on cancer such as targeting on several pathways, reducing adverse side effects, and altering drug metabolism and excretion (Liu and Cheng, 2012; Cao *et al.*, 2011).

Dillenia suffruticosa (Griffith ex Hook. F. and Thomson) Martelli (Family: Dilleniaceae), commonly known as “*Simpoh air*”, is found abundantly in the secondary forest and swampy ground of Malaysia. This plant is traditionally used for the treatment of cancerous growth (Ahmad and Holdsworth, 1995). Previous studies revealed that the root hot water extract of *D. suffruticosa* has anti-cervical (Said, 2010) and anti-colon cancer properties (Husain, 2010). In addition, root dichloromethane extract of *D. suffruticosa* (DCM-DS) from sequential solvent extraction exhibited strong cytotoxicity towards human MCF-7 and MDA-MB-231 breast cancer cells (Armania *et al.*, 2013). Therefore, *D. suffruticosa* has a great potential to be developed as evidence-based complementary and alternative medicine for the treatment of breast cancer

The general objective of this study was to determine the mode of cell death and the signalling pathways involved in MCF-7 and MDA-MB-231 breast cancer cells treated with DCM-DS.

The specific objectives of this study were:

1. To determine the cell cycle profile and mode of cell death of DCM-DS treated MCF-7 and MDA-MB-231 breast cancer cells.
2. To determine the involvement of ROS in the cytotoxicity of DCM-DS towards MCF-7 and MDA-MB-231 cells.
3. To determine the expression of apoptotic, growth, survival genes and proteins of MCF-7 and MDA-MB-231 breast cancer cells treated with DCM-DS.
4. To isolate and identify the compounds in DCM-DS.

It was hypothesised that DCM-DS will induce cell cycle arrest, apoptosis and generation of ROS to induce cell death in MCF-7 and MDA-MB-231 breast cancer cells via multiple signalling pathways. The compounds in DCM-DS will be isolated and identified.

REFERENCES

- Abd-El-Rehim, D.M., Ball, G., Pinder, S.E., Rakha, E., Paish, C., Robertson, J.F., Macmillan, D., Blamey, R.W. and Ellis, I.O. 2005. High-throughput protein expression analysis using tissue microarray technology of a large well characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. *International Journal of Cancer* 116: 340-350.
- Abdille, M.H., Singh, R.P., Jayaprakasha, G.K. and Jena, B.S. 2005. Antioxidant activity of the extracts from *Dillenia indica* fruits. *Food Chemistry* 90: 891-896.
- Abhyankara, G., Suprasannab, P., Pandeyc, B.N., Mishrac, K.P., Raoa, K.V. and Reddy, V.D. 2010. Hairy root extract of *Phyllanthus amarus* induces apoptotic cell death in human breast cancer cells. *Innovative Food Science and Emerging Technologies* 11: 526-532.
- Adams, C., Allison, D., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKeever, K. and Sliwkowski, M. 2006. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. *Cancer Immunology Immunotherapy* 55: 717-727.
- Adams, L.S., Kanaya, N., Phung, S., Liu, Z. and Chen, S. 2011. Whole blueberry powder modulates the growth and metastasis of MDA-MB-231 triple negative breast tumors in nude mice. *Journal of Nutrition* 141: 1805-1812.
- Aebi, S., Sun, Z., Braun, D., Price, K.N., Castiglione-Gertsch, M., Rabaglio, M., Gelber, R.D., Crivellari, D., Lindtner, J., Snyder, R., Karlsson, P., Simoncini, E., Gusterson, B.A., Viale, G., Regan, M.M., Coates, A.S. and Goldhirsch, A. 2011. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. *Annals of Oncology* 22: 1981-1987.
- Ahmad, R. and Abdullah, N. 2013. Mechanism of action. In *Antioxidant principles and in vitro evaluation methods*, ed. R. Ahmad, pp. 3-19. Shah Alam: UiTM Press.
- Ahmad, F.B. and Holdsworth, D.K. 1995. Traditional medicinal plants of Sabah, Malaysia part III. The Rungus people of Kudat. *International Journal of Pharmacognosy* 33: 262-264.
- Akbas, S.H., Timur, M. and Ozben, T. 2005. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB-231 human breast cancer cells. *Journal of Surgical Research* 125: 49-55.
- Alam, M.B., Chowdhury, N.S., Mazumder, M.E.H. and Haque, M.E. 2011. Antimicrobial and toxicity study of different fractions of *Dillenia indica* Linn. bark extract. *International of Pharmaceutical Sciences and Research* 2: 860-866.

- Albain, K.S., Barlow, W.E., Shak, S., Hortobagyi, G.N., Livingston, R.B., Yeh, I.T., Ravdin, P., Bugarini, R., Baehner, F.L., Davidson, N.E., Sledge, G.W., Winer, E.P., Hudis, C., Ingle, J.N., Perez, E.A., Pritchard, K.I., Shepherd, L., Gralow, J.R., Yoshizawa, C., Allred, D.C., Osborne, C.K. and Hayes, D.F. 2010. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncology* 11: 55-65.
- Al-Dhaheri, Y., Eid, A., AbuQamar, S., Attoub, S., Khasawneh, M., Aiche, G., Hisaindee, S. and Iratni, R. 2013. Mitotic arrest and apoptosis in breast cancer cells induced by *Origanum majorana* extract: upregulation of TNF- α and downregulation of survivin and mutant p53. *PLoS ONE* 8: e56649, 14 pages.
- Al-Halabi, R., Chedid, M.B., Merhi, R.A., El-Hajj, H., Zahr, H., Schneider-Stock, R., Bazarbachi, A. and Gali-Muhtasib, H. 2011. Gallotannin inhibits NF κ B signaling and growth of human colon cancer xenografts. *Cancer Biology and Therapy* 12: 59-68.
- Alkhalaf, M. and El-Mowafy, A.M. 2003. Overexpression of wild-type p53 gene renders MCF-7 breast cancer cells more sensitive to the antiproliferative effect of progesterone. *Journal of Endocrinology* 179: 55-62.
- Alzweiri, M., Al-Sarhan, A., Mansi, K., Hudaib, M. and Aburjai, T. 2011. Ethnopharmacological survey of medicinal herbs in Jordan, the Northern Badia region. *Journal of Ethnopharmacology* 137: 27-35.
- American Cancer Society 2014. How is breast cancer staged? <http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-staging>. Retrieved 9th November 2014.
- Andel, T.V. and Havinga, R. 2008. Sustainability aspects of commercial medicinal plant harvesting in Suriname? *Forest Ecology and Management* 256: 1540-1545.
- Andel, T.V. and Westers, P. 2010. Why Surinamese migrants in the Netherlands continue to use medicinal herbs from their home country? *Journal of Ethnopharmacology* 127: 694-701.
- André, F. and Zielinski, C.C. 2012. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. *Annals of Oncology* 23: 46-51.
- Antony, M.L., Kim, S.H. and Singh, S.V. 2012. Critical role of p53 upregulated modulator of apoptosis in benzyl isothiocyanate-induced apoptotic cell death. *PLoS ONE* 7: e32267, 11 pages.
- Apu, A.S., Muhit, M.S., Tareq, S.M., Pathan, A.H., Jamaluddin, A.T.M. and Ahmed, M. 2010. Antimicrobial activity and brine shrimp lethality bioassay of the leaves extract of *Dillenia indica* Linn. *Journal of Young Pharmacist* 2: 50-53.

- Armania, N., Latifah, S.Y., Musa, S.N., Ismail, I.S., Foo, J.B., Chan, K.W., Noreen, H., Hisyam, A.H., Zulfahmi, S. and Ismail, M. 2013. *Dillenia suffruticosa* exhibited antioxidant and cytotoxic activity through induction of apoptosis and G₂/M cell cycle arrest. *Journal of Ethnopharmacology* 146: 525-535.
- Arthur, J.S. and Ley, S.C. 2013. Mitogen-activated protein kinases in innate immunity. *Nature Reviews Immunology* 13: 679-692.
- Azizi, A., Boscoboinik, D., Clement, S., Marilley, D., Ozer, N.K., Ricciarelli, R. and Tasinato, A. 1998. Control of cell proliferation by α -tocopherol. In *Cell growth and oncogenesis*, ed. P. Bannasch, D. Kanduc, S. Papa and J.M. Tager, pp. 161-176. Basel: Birkhauser Verlag.
- Badajatia, N., Satyam, A., Singh, P., Seth, A. and Sharma, A. 2010. Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. *Urologic Oncology* 28: 360-367.
- Balasundram, N., Sundram, K. and Saman, S. 2006. Phenolic compounds in plants and agriindustrial by products: Antioxidant activity, occurrence, and potential uses. *Food Chemistry* 99: 191-203.
- Balmanno, K. and Cook, S.J. 2009. Tumour cell survival signalling by the ERK1/2 pathway. *Cell Death and Differentiation* 16: 368-377.
- Banerji, N., Majumder, P. and Dutta, N.C. 1975. A new pentacyclic triterpenes lactone from *Dillenia indica*. *Phytochemistry* 14: 1447-1448.
- Bartek, J. and Lukas, J. 2001. Mammalian G₁- and S-phase checkpoints in response to DNA damage. *Current Opinion in Cell Biology* 13: 738-747.
- Baselga, J. 2011. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. *Oncologist* 16: 12-19.
- Baselga, J., Gelmon, K.A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V.A., Ross, G.A., Fumoleau, P. and Gianni, L. 2010. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer that progressed during prior trastuzumab therapy. *Journal of Clinical Oncology* 28: 1138-1144.
- Batra, P. and Sharma, A.K. 2013. Anti-cancer potential of flavonoids: recent trends and future perspectives. *3 Biotech* 3: 439-459.
- Batsi, C., Markopoulou, S., Kontargiris, E., Charalambous, C., Thomas, C., Christoforidis, S., Kanavaros, P., Constantinou, A.I., Marcu, K.B. and Kolettas, E. 2009. Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27^{Kip1}-dependent G1/S cell cycle arrest in conjunction with NF- κ B activation. *Biochemical Pharmacology* 78: 33-44.
- Bele, A.A. and Khale, A. 2012. Standardization of herbal drugs: An overview. *International Research Journal of Pharmacy* 2: 56-60.

- Belousova, N., Mikheeva, G., Xiong, C., Soghomonian, S., Young, D., Le-Roux, L., Naff, K., Bidaut, L., Wei, W., Li, C., Gelovani, J. and Krasnykh, V. 2010. Development of a targeted gene vector platform based on simian adenovirus serotype 24. *Journal of Virology* 84: 10087-10101.
- Berge, T.V., Linkermann, A., Jouan-Lanhouet, S., Walczak, H. and Vandenabeele, P. 2014. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. *Nature Reviews Molecular Cell Biology* 15: 135-147.
- Bergström, T., Ersson, C., Bergman, J. and Möller, L. 2012. Vitamins at physiological levels cause oxidation to the DNA nucleoside deoxyguanosine and to DNA-alone or in synergism with metals. *Mutagenesis* 27: 511-517.
- Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, M., Mandelblatt, J.S., Yakovlev, A.Y., Habbema, J.D.F. and Feuer, E.J. 2005. Effect of screening and adjuvant therapy on mortality from breast cancer. *New England Journal of Medicine* 353: 1784-1792.
- Berthois, Y., Katzenellenbogen, J.A. and Katzenellenbogen, B.S. 1986. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. *Proceedings of the National Academy of Sciences* 83: 2496-2500.
- Bode, A.M. and Dong, Z. 2007. The functional contrariety of JNK. *Molecular Carcinogenesis* 46: 591-598.
- Bogoyevitch, M.A., Ngoei, K.R., Zhao, T.T., Yeap, Y.Y. and Ng, D.C. 2010. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. *Biochimica et Biophysica Acta* 1804: 463-475.
- Bonelli, M.A., Fumarola, C., Alfieri, R.R., La-Monica, S., Cavazzoni, A., Galetti, M., Gatti, R., Belletti, S., Harris, A.L., Fox, S.B., Evans, D.B., Dowsett, M., Martin, L.A., Bottini, A., Generali, D. and Petronini, P.G. 2010. Synergistic activity of letrozole and sorafenib on breast cancer cells. *Breast Cancer Research and Treatment* 124: 79-88.
- Boyed, M.R. 1997. The NCI *in vitro* anticancer drug discovery screen. In *Anticancer drug development guide; preclinical screening, clinical trials and approval*, ed. B. Teicher, pp.30. Totowa: Humana Press.
- Bradford, M.M. 1976. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry* 72: 248-254.
- Bradley, J.R. and Pober, J.S. 2001. Tumor necrosis factor receptor-associated factors (TRAFs). *Oncogene* 20: 6482-6491.
- Brahma, B., Prasad, S.B., Verma, A.K. and Rosangkima, G. 2011. Study of the antitumor efficacy of some select medicinal plants of assam against murine ascites Dalton's lymphoma. *Pharmacologyonline* 3: 155-168.

- Bratton, M.R., Duong, B.N., Elliott, S., Weldon, C.B., Beckman, B.S., McLachlan, J.A. and Burow, M.E. 2010. Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival. *International Journal of Oncology* 37: 541-550.
- Breitmaier, E. 2006. Terpenes: Importance, general structure, and biosynthesis. In: *Terpenes: Flavors, fragrances, pharmaca, pheromones*, ed. E. Breitmaier, pp. 1-9. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA.
- Breitschopf, K., Haendeler, J., Malchow, P., Zeiher, A.M. and Dimmeler, S. 2000. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. *Molecular and Cellular Biology* 20: 1886-1896.
- Broadhead, C.L. and Combes, R.D. 2001. The current status of food additives toxicity testing and the potential for application of the three Rs. *Alternatives to Laboratory Animals* 29: 471-485.
- Brunelle, J.K. and Letai, A. 2009. Control of mitochondrial apoptosis by the Bcl-2 family. *Journal of Cell Science* 122: 437-441.
- Burstein, H.J., Sun, Y., Dirix, L.Y., Jiang, Z., Paridaens, R., Tan, A.R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., Abbas, R., Powell, C., Turnbull, K., Vermette, J., Zacharchuk, C. and Badwe, R. 2010. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. *Journal of Clinical Oncology* 28: 1301-1307.
- Cadenas, E. and Davis, K.J.A. 2000. Mitochondria free radical generation, oxidative stress, and aging. *Free Radical Biology and Medicine* 29: 222-230.
- Cailleau, R., Young, R., Olivé, M. and Reeves, W.J.J. 1974. Breast tumor cell lines from pleural effusions. *Journal of the National Cancer Institute* 53: 661-674.
- Calcabrini, A., García-Martínez, J.M., González, L., Tendero, M.J., Ortuño, M.T., Crateri, P., Lopez-Rivas, A., Arancia, G., González-Porqué, P. and Martín-Pérez, J. 2006. Inhibition of proliferation and induction of apoptosis in human breast cancer cells by lauryl gallate. *Carcinogenesis* 27: 1699-1712.
- Cancer Research UK 2014. TNM breast cancer staging. <http://www.cancerresearchuk.org/about-cancer/type/breast-cancer/treatment/tnm-breast-cancer-staging>. Retrieved 9th November 2014.
- Cao, P., Cai, X.T., Lu, W.G., Zhou, F. and Huo, J.G. 2011. Growth inhibition and induction of apoptosis in SHG-44 glioma gells by Chinese medicine formula "Pingliu Keli". *Evidence-Based Complementary and Alternative Medicine* 2011: Article ID 958243, 9 pages.

- Cardinale, D., Colombo, A., Torrisi, R., Sandri, M.T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M.A., Nolè, F., Veglia, F. and Cipolla, C.M. 2010. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. *Journal of Clinical Oncology* 28: 3910-3916.
- Carey, L.A., Perou, C.M., Livasy, C.A., Dressler, L.G., Cowan, D., Conway, K., Karaca, G., Troester, M.A., Tse, C.K., Edmiston, S., Deming, S.L., Geradts, J., Cheang, M.C.U., Nielsen, T.O., Moorman, P.G., Earp, H.S. and Millikan, R.C. 2006. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. *Journal of the American Medical Association* 295: 2492-2502.
- Cargnello, M. and Roux, P.P. 2011. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiology and Molecular Biology Reviews* 75: 50-83.
- Cass, G. 1990. A history of the Michigan Cancer Foundation, the beginnings & growth of Detroit's anticancer movement. Detroit: Michigan Cancer Foundation.
- Cellurale, C., Girnius, N., Jiang, F., Cavanagh Kyros, J., Lu, S., Garlick, D.S., Mercurio, A.M. and Davis, R.J. 2012. Role of JNK in mammary gland development and breast cancer. *Cancer Research* 72: 472-481.
- Chand, N., Cutress, R.I., Oepfen, R.S. and Agrawal, A. 2013. Staging investigations in breast cancer: Collective opinion of UK breast surgeons. *International Journal of Breast Cancer* 2013: Article ID 506172, 8 pages.
- Chang, T.L. and Wang, C.H. 2013. Combination of quercetin and tannic acid in inhibiting 26S proteasome affects S5a and 20S expression, and accumulation of ubiquitin resulted in apoptosis in cancer chemoprevention. *Biological Chemistry* 394: 561-575.
- Chatterjee, P., Kouzi, S.A., Pezzuto, J.M. and Hamann, M.T. 2000. Biotransformation of the antimelanoma agent betulinic acid by *Bacillus megaterium* ATCC 13368. *Applied and Environmental Microbiology* 66: 3850-3855.
- Chaudhary, P., Sharma, R., Sharma, A., Vatsyayan, R., Yadav, S., Singhal, S.S., Rauniyar, N., Prokai, L., Awasthi, S. and Awasthi, Y.C. 2010. Mechanisms of 4-hydroxy-2-nonenal induced pro- and anti-apoptotic signaling. *Biochemistry* 49: 6263-6275.
- Chawla, R., Thakur, P., Chowdhry, A., Jaiswal, S., Sharma, A., Goel, R., Sharma, J., Priyadarshi, S.S., Kumar, V., Sharma, R.K. and Arora, R. 2013. Evidence-based herbal drug standardization approach in coping with challenges of holistic management of diabetes: a dreadful lifestyle disorder of 21st century. *Journal of Diabetes and Metabolic Disorders* 12: Article 35, 16 pages.
- Chen, R.J.Y., Chung, T.Y., Li, F.Y., Lin, N.H. and Tzen, J.T.C. 2009. Effect of sugar positions in ginsenosides and their inhibitory potency on Na⁺/K⁺-ATPase activity. *Acta Pharmacologica Sinica* 30: 61-69.

- Chen, Z., Gibson, T.B., Robinson, F., Silvestro, L., Pearson, G., Xu, B., Wright, A., Vanderbilt, C. and Cobb, M.H. 2001. MAP kinases. *Chemical Reviews* 101: 2449-2476.
- Chen, X., Sun, L., Cong, Y., Zhang, T., Lin, Q., Meng, Q., Pang, H., Zhao, Y., Li, Y., Cai, L. and Dong, X. 2014. Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer. *Journal of Experimental and Clinical Cancer Research* 33: Article 28, 6 pages.
- Chin, Y.R. and Toker, A. 2010. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. *Molecular Cell* 38: 333-344.
- Chintharlapalli, S., Papineni, S., Lei, P., Pathi, S. and Safe, S. 2011. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. *BMC Cancer* 11: Article 371, 12 pages.
- Choudhary, N. and Sekhon, B.S. 2011. An overview of advances in the standardization of herbal drugs. *Journal of Pharmaceutical Education and Research* 2: 55-70.
- Chua, P.J., Yip, G.W.C. and Bay, B.H. 2009. Cell cycle arrest induced by hydrogen peroxide is associated with modulation of oxidative stress related genes in breast cancer cells. *Experimental Biology and Medicine* 234: 1086-1094.
- Coates, A.S., Colleoni, M. and Goldhirsch, A. 2012. Is adjuvant chemotherapy useful for women with luminal A breast cancer? *Journal of Clinical Oncology* 30: 1260-1263.
- Colegate, S.M. and Molyneux, R.J. 2008. An introduction and overview. In *Bioactive natural products detection, isolation and structural determination*, ed. S.M. Colegate, and R.J. Molyneux, pp. 1-9. Boca Raton: CRC Press.
- Collins, K.K., Liu, Y., Schootman, M., Aft, R., Yan, Y., Dean, G., Eilers, M. and Jeffe, D.B. 2011. Effects of breast cancer surgery and surgical side effects on body image over time. *Breast Cancer Research and Treatment* 126: 167-176.
- Cooper, J.A., Bowen Pope, D.F., Raines, E., Ross, R. and Hunter, T. 1982. Similar effects of platelet-derived growth factor and epidermal growth factor on the phosphorylation of tyrosine in cellular proteins. *Cell* 31: 263-273.
- Cosentino-Gomes, D., Rocco-Machado, N. and Meyer-Fernandes, J.R. 2012. Cell signaling through protein kinase C oxidation and activation. *International Journal of Molecular Sciences* 13: 10697-10721.
- Coulombe, P. and Meloche, S. 2007. Atypical mitogen-activated protein kinases: structure, regulation and functions. *Biochimica et Biophysica Acta* 1773: 1376-1387.
- Crowley, K.J. 1964. Some terpenic constituents of *Bursera graveolens* (H. B. K.) Tr. et Pl. var. *villosula* Cuatr. *Journal of the Chemical Society* 1964: 4254-4256.

- Cseh, B., Doma, E. and Baccarini, M. 2014. "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. *FEBS Journal* 588: 2398-2406.
- Cuadrado, A. and Nebreda, A.R. 2010. Mechanisms and functions of p38MAPK signalling. *Biochemical Journal* 429: 403-417.
- Cuenda, A. and Rousseau, S. 2007. p38MAP-kinases pathway regulation, function and role in human diseases. *Biochimica et Biophysica Acta* 1773: 1358-1375.
- Cunha, S., Lin, Y.C., Goossen, E.A., DeVette, C.I., Albertella, M.R., Thomson, S., Mulvihill, M.J. and Welm, A.L. 2014. The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. *Cell Reports* 6: 141-154.
- Curigliano, G. 2012. New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance. *Cancer Treatment Reviews* 38: 303-310.
- Curigliano, G., Bagnardi, V., Viale, G., Fumagalli, L., Rotmensz, N., Aurilio, G., Locatelli, M., Pruneri, G., Giudici, S., Bellomi, M., Della Vigna, P., Monfardini, L., Orsi, F., Nolè, F., Munzone, E. and Goldhirsch, A. 2011. Should liver metastases of breast cancer be biopsied to improve treatment choice? *Annals of Oncology*: 2227-2233.
- Czabotar, P.E., Lessene, G., Strasser, A. and Adams, J.M. 2014. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. *Nature Reviews Molecular Cell Biology* 15: 49-63.
- Damle, A.A., Pawar, Y.P. and Narkar, A.A. 2013. Anticancer activity of betulinic acid on MCF-7 tumors in nude mice. *Indian Journal of Experimental Biology* 51: 485-491.
- Das, G.C., Holiday, D., Gallardo, R. and Haas, C. 2001. Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. *Cancer Letters* 165: 147-153.
- Das, M., Sarma, B.P., Ahmed, G., Nirmala, C.B. and Choudhury, M.K. 2012. *In vitro* anti-oxidant activity total phenolic content of *Dillenia indica* and *Garcinia penducalata*, commonly used fruits in Assamese cuisine. *Free Radicals and Antioxidants* 2: 30-36.
- Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M.E. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell* 91: 231-241.
- Deeb, D., Gao, X., Liu, Y.B., Pindolia, K. and Gautam, S.C. 2014. Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF- κ B/mTOR signaling proteins and anti-apoptotic Bcl-2. *International Journal of Oncology* 44: 1707-1715.

- Dehelean, C.A., Şoica, C., Ledeti, I., Aluaş, M., Zupko, I., Găluşcan, A., Cinta-Pinzaru, S. and Munteanu, M. 2012. Study of the betulin enriched birch bark extracts effects on human carcinoma cells and ear inflammation. *Chemistry Central Journal* 6: Article 137, 9 pages.
- Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., Lickley, L.A., Rawlinson, E., Sun, P. and Narod, S.A. 2007. Triple-negative breast cancer: clinical features and patterns of recurrence. *Clinical Cancer Research* 13: 4429-4434.
- Dérijard, B., Raingeaud, J., Barrett, T., Wu, I.H., Han, J., Ulevitch, R.J. and Davis, R.J. 1995. Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. *Science* 267: 682-685.
- Devarajan, E., Sahin, A.A., Chen, J.S., Krishnamurthy, R.R., Aggarwal, N., Brun, A.M., Sapino, A., Zhang, F., Sharma, D., Yang, X.H., Tora, A.D. and Mehta, K. 2002. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. *Oncogene* 21: 8843-8851.
- Dhillon, K.K., Swisher, E.M. and Taniguchi, T. 2011. Secondary mutations of *BRCA1/2* and drug resistance. *Cancer Science* 102: 663-669.
- Din, O.S., Dodwell, D., Winter, M.C., Mori, S. and Coleman, R.E. 2011. Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK. *Clinical Oncology* 23: 674-680.
- Dolgin, E. 2011. When it takes two to tango, FDA suggests a new regulatory dance. *Nature Medicine* 17: 270.
- Du, J., Xu, R., Hu, Z.Z., Tian, Y.H., Zhu, Y.C., Gu, L. and Zhou, L. 2011. PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1 α expression in MCF-7 breast cancer cells. *PLoS ONE* 6: e25213, 9 pages.
- Du, Y., Wolf, I.K., Zhuang, W., Bodemann, S., Knöss, W. and Knopf, H. 2014. Use of herbal medicinal products among children and adolescents in Germany. *BMC Complementary and Alternative Medicine* 14: Article 218, 13 pages.
- Dung, N.X. and Loi, D.T. 1991. Selection of traditional medicines for study. *Journal of Ethnopharmacology* 32: 57-70.
- Eisenbrand, G., Pool-Zobel, B., Baker, V., Balls, M., Blaauboer, B.J., Boobis, A., Carere, A., Kevekordes, S., Lhuguenot, J.C., Pieters, R. and Kleiner, J. 2002. Methods of *in vitro* toxicology. *Food and Chemical Toxicology* 40: 193-236.
- Ekka, N.R., Namdeo, K.P. and Samal, P.K. 2008. Standardisation strategies for herbal drugs-an overview. *Research Journal of Pharmacy and Technology* 1: 310-312.
- Ekor, M. 2014. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Frontier in Pharmacology* 4: Article 177, 10 pages.

- El-Shemy, H.A., Aboul-Enein, A.M., Aboul-Enein, K.M. and Fujita, K. 2007. Willow leaves' extracts contain anti-tumor agents effective against three cell types. *PLoS ONE* 2: e178, 5 pages.
- Engel, T. and Henshall, D.C. 2009. Apoptosis, Bcl-2 family proteins and caspases: the ABCs of seizure-damage and epileptogenesis? *International Journal of Physiology, Pathophysiology and Pharmacology* 1: 97-115.
- Essmann, F., Engels, I.H., Totzke, G., Schulze-Osthoff, K. and Jänicke, R.U. 2004. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. *Cancer Research* 64: 7065-7072.
- Evan, G.I. and Vousden, K.H. 2001. Proliferation, cell cycle and apoptosis in cancer. *Nature* 411: 342-348.
- Fabbri, F., Carloni, S., Briigliadori, G., Zoli, W., Lapalombella, R. and Marini, M. 2006. Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: A cytometric study. *BMC Cell Biology* 7: Article 6, 14 pages.
- Fahrman, J.F. and Hardman, W.E. 2013. Omega 3 fatty acids increase the chemosensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine. *Lipids in Health and Disease* 12: Article 36, 13 pages.
- Fang, X., Yu, S., Eder, A., Mao, M., Bast, R.C., Boyd, D. and Mills, G.B. 1999. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. *Oncogene* 18: 6635-6640.
- Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N.J., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., Martin, N.M.B., Jackson, S.P., Smith, G.C.M. and Ashworth, A. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 434: 917-921.
- FDA 2013. FDA approves new treatment for late-stage breast cancer. <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm340704.htm>. Retrieved 19th December 2014.
- Ferguson, P.J., Phillips, J.R., Selner, M. and Cass, C.E. 1984. Differential activity of vincristine and vinblastine against cultured cells. *Cancer Research* 44: 3307-3312.
- Foulkes, W.D., Brunet, J.S., Stefansson, I.M., Straume, O., Chappuis, P.O., Bégin, L.R., Hamel, N., Goffin, J.R., Wong, N., Trudel, M., Kapusta, L., Porter, P. and Akslen, L.A. 2004. The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) phenotype of BRCA1-related breast cancer. *Cancer Research* 64: 830-835.
- Franke, T.F., Kaplan, D.R., Cantley, L.C. and Toker, A. 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. *Science* 275: 665-668.

- Fuchs, Y. and Steller, H. 2011. Programmed cell death in animal development and disease. *Cell* 147: 742-758.
- Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nuñez, G., Krammer, P.H., Peter, M.E. and Debatin, K.M. 1997. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. *Cancer Research* 57: 4956-4964.
- Fulda, S., Susin, S.A., Kroemer, G. and Debatin, K.M. 1998. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. *Cancer Research* 58: 4453-4460.
- Gao, C.M., Takezaki, T., Wu, J.Z., Liu, Y.T., Ding, J.H., Li, S.P., Su, P., Hu, X., Kai, H.T., Li, Z.Y., Matsuo, K., Hamajima, N., Sugimura, H. and Tajima, K. 2004. Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susceptibility to esophageal and stomach cancer with smoking. *Asian Pacific Journal of Cancer Prevention* 5: 133-138.
- Garg, V., Dhar, V.J., Sharma, A. and Dutt, R. 2012. Facts about standardization of herbal medicine: A review. *Journal of Chinese Integrative Medicine* 10: 1077-1083.
- Garofalo, R.S., Orena, S.J., Rafidi, K., Torchia, A.J., Stock, J.L., Hildebrandt, A.L., Coskran, T., Black, S.C., Brees, D.J., Wicks, J.R., McNeish, J.D. and Coleman, K.G. 2003. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB β . *Journal of Clinical Investigation* 112: 197-208.
- GLOBOCAN 2012. Breast cancer: Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Retrieved 3rd September 2014.
- Gökmen-Polar, Y., Mehta, R., Tuzmen, S., Mousses, S., Thorat, M.A., Sanders, K.L., Turbin, D., Leung, S., Huntsman, D.G., Sledge, G.W.J. and Badve, S. 2010. Differential subcellular expression of protein kinase C betall in breast cancer: correlation with breast cancer subtypes. *Breast Cancer Research and Treatment* 124: 327-335.
- Gopalakrishna, R. and Anderson, W.B. 1989. Ca²⁺- and phospholipid-independent activation of protein kinase C by selective oxidative modification of the regulatory domain. *Proceedings of the National Academy of Sciences* 86: 6758-6762.
- Goralczyk, R. and Siler, U. 2005. The role of lycopene in human health. In *Phytochemicals in health and disease*, ed. Y.P. Bao and R. Fenwick, pp. 255-275. New York: Marcel Dekker.
- Grosvenor, P.W., Gothard, P.K., McWdham, N.C., Supriono, A. and Gray, D.O. 1995a. Medicinal plants from Riau Province, Sumatra, Indonesia. Part 1: Uses. *Journal of Ethnopharmacology* 45: 75-95.

- Grosvenor, P.W., Supriono, A. and Gray, D.O. 1995b. Medicinal plants from Riau Province, Sumatra, Indonesia. Part 2: Antibacterial and antifungal activity. *Journal of Ethnopharmacology* 45: 97-111.
- Gurtner, A., Starace, G., Norelli, G., Piaggio, G., Sacchi, A. and Boss, G. 2010. Mutant p53-induced upregulation of mitogen-activated protein kinase 3 contributes to gain of function. *Journal of Biological Chemistry* 285: 14160-14169.
- Halawani, D., Mondeh, R., Stanton, L.A. and Beier, F. 2004. p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation. *Oncogene* 23: 3726-3731.
- Han, J., Lee, J.D., Jiang, Y., Li, Z., Feng, L. and Ulevitch, R.J. 1996. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). *Journal of Biological Chemistry* 271: 2886-2891.
- Hanahan, D. and Weinberg, R.A. 2000. The hallmarks of cancer. *Cell* 100: 57-70.
- Hanum, F. and Hamzah, N. 1999. The use of medicinal plant species by the Temuan Tribe of Ayer Hitam Forest, Selangor, Peninsular Malaysia. *Pertanika Journal of Tropical Agricultural Sciences* 22: 85-94.
- Hayashi, Y., Kuroda, T., Kishimoto, H., Wang, C., Iwama, A. and Kimura, K. 2014. Downregulation of rRNA transcription triggers cell differentiation. *PLoS ONE* 9: e98586, 10 pages.
- Hayden, M.S. and Ghosh, S. 2004. Signaling to NF-kappaB. *Genes and Development* 18: 2195-2224.
- Hensley, K., Benaksas, E.J., Bolli, R., Comp, P., Grammas, P., Hamdheydari, L., Mou, S., Pye, Q.N., Stoddard, M.F., Wallis, G., Williamson, K.S., West, M., Wechter, W.J. and Floyd, R.A. 2004. New perspectives on vitamin E: Gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. *Free Radical Biology and Medicine* 36: 1-15.
- Herschkowitz, J.I., Simin, K., Weigman, V.J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K.E., Jones, L.P., Assefnia, S., Chandrasekharan, S., Backlund, M.G., Yin, Y., Khramtsov, A.I., Bastein, R., Quackenbush, J., Glazer, R.I., Brown, P.H., Green, J.E., Kopelovich, L., Furth, P.A., Palazzo, J.P., Olopade, O.I., Bernard, P.S., Churchill, G.A., Van Dyke, T. and Perou, C.M. 2007. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biology* 8: Article R76, 17 pages.
- Hicks, D.G., Short, S.M., Prescott, N.L., Tarr, S.M., Coleman, K.A., Yoder, B.J., Crowe, J.P., Choueiri, T.K., Dawson, A.E., Budd, G.T., Tubbs, R.R., Casey, G. and Weil, R.J. 2006. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. *American Journal of Surgical Pathology* 30: 1097-1104.

- Ho, K.L., Latifah, S.Y., Ismail, N. and Ismail, M. 2009. Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin. *Cancer Epidemiology* 33: 155-160.
- Hoe, K.K., Verma, C.S. and Lane, D.P. 2014. Drugging the p53 pathway: understanding the route to clinical efficacy. *Nature Reviews Drug Discovery* 13: 217-236.
- Holliday, D.L. and Speirs, V. 2011. Choosing the right cell line for breast cancer research. *Breast Cancer Research* 13: Article 215, 7 pages.
- Holohan, C., Van Schaeysbroeck, S., Longley, D.B. and Johnston, P.G. 2013. Cancer drug resistance: An evolving paradigm. *Nature Reviews Cancer* 13: 714-726.
- Horie, N., Hirabayashi, N., Takahashi, Y., Miyauchi, Y., Taguchi, H. and Takeishi, K. 2005. Synergistic effect of green tea catechins on cell growth and apoptosis induction in gastric carcinoma cells. *Biological and Pharmaceutical Bulletin* 28: 574-579.
- Hou, D.X., Tong, X., Terahara, N., Luo, D. and Fujii, M. 2005. Delphinidin 3-sambubioside, a *Hibiscus anthocyanin*, induces apoptosis in human leukemia cells through reactive oxygen species-mediated mitochondrial pathway. *Archives of Biochemistry and Biophysics* 440: 101-109.
- Howlander, N., Noone, A.M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J. and Cronin, K.A. 2013. *SEER Cancer Statistics Review, 1975-2011*. National Cancer Institute: Bethesda.
- Hsiao, C.J., Hsiao, G., Chen, W.L., Wang, S.W., Chiang, C.P., Liu, L.Y., Guh, J.H., Lee, T.H. and Chung, C.L. 2014. Cephalochromin induces G₀/G₁ cell cycle arrest and apoptosis in A549 human non-small-cell lung cancer cells by inflicting mitochondrial disruption. *Journal of Natural Products* 77: 758-765.
- Hsu, M.H., Kuo, S.C., Chen, C.J., Chung, J.G., Lai, Y.Y. and Huang, L.J. 2005. 1-(3,4-dimethoxyphenyl)-3,5-dodecenedione (I6) induces G₁ arrest and apoptosis in human promyelocytic leukemia HL-60 cells. *Leukemia Research* 29: 1399-1406.
- Huang, K.F., Zhang, G.D., Huang, Y.Q. and Diao, Y. 2012. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway. *International Immunopharmacology* 12: 334-341.
- Hui, C., Qi, X., Qianyong, Z., Xiaoli, P., Jundong, Z. and Mantian, M. 2013. Flavonoids, flavonoid subclasses and breast cancer risk: A meta-analysis of epidemiologic studies. *PLoS ONE* 8: e54318, 8 pages.
- Hui, L., Zheng, Y., Yan, Y., Bargonetti, J. and Foster, D.A. 2006. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. *Oncogene* 25: 7305-7310.

- Hunter, K.W., Crawford, N.P. and Alsarraj, J. 2008. Mechanisms of metastasis. *Breast Cancer Research* 10: Article S2, 10 pages.
- Hupp, T.R., Lane, D.P. and Ball, K.L. 2000. Strategies for manipulating the p53 pathway in treatment of human cancer. *Biochemistry Journal* 352: 1-17.
- Husain, N. 2010. *Anticorectal cancer properties of Dillenia suffruticosa (Griffith Ex. Hook. F. & Thomson) Martelli water extract in in vitro and in vivo models*, Master Thesis, Universiti Putra Malaysia.
- Huseby, R.A., Maloney, T.M. and McGrath, C.M. 1984. Evidence for a direct growth-stimulating effect of estradiol on human MCF-7 cells *in vivo*. *Cancer Research* 44: 2654-2659.
- Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Naga Prasad, S.V., Mutharasan, R.K., Naik, T.J. and Ardehali, H. 2014. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. *Journal of Clinical Investigation* 124: 617-630.
- Im, D.S. and Nah, S.Y. 2013. Yin and Yang of ginseng pharmacology: ginsenosides vs gintonin. *Acta Pharmacologica Sinica* 34: 1367-1373.
- Imanishi, Y., Hu, B., Xiao, G., Yao, X. and Cheng, S.Y. 2011. Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway. *Journal of Biological Chemistry* 286: 29249-29260.
- Inoue, H. and Tani, K. 2014. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. *Cell Death and Differentiation* 21: 39-49.
- Inoue, M., Suzuki, R., Sakaguchi, N., Li, Z., Takeda, T., Ogihara, Y., Jiang, B.Y. and Chen, Y.J. 1995. Selective induction of cell death in cancer cells by gallic acid. *Biological and Pharmaceutical Bulletin* 18: 1526-1530.
- Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., Honma, Y. and Hayashi, J. 2008. ROS generating mitochondrial DNA mutations can regulate tumor cell metastasis. *Science* 320: 661-664.
- Jada, S.R., Matthews, C., Saad, M.S., Hamzah, A.S., Lajis, N.H., Stevens, M.F.G. and Stanslas, J. 2008. Benzylidene derivatives of andrographolide inhibit growth of breast and colon cancer cells *in vitro* by inducing G1 arrest and apoptosis. *British Journal of Pharmacology* 155: 641-654.
- Jagsi, R. 2014. Progress and controversies: Radiation therapy for invasive breast cancer. *CA: A Cancer Journal for Clinicians* 64: 135-152.
- Jänicke, R.U. 2009. MCF-7 breast carcinoma cells do not express caspase-3. *Breast Cancer Research and Treatment* 117: 219-221.

- Jänicke, R.U., Engels, I.H., Dunkern, T., Kaina, B., Schulze-Osthoff, K. and Porter, A.G. 2001. Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells. *Oncogene* 20: 5043-5053.
- Jänicke, R.U., Sprengart, M.L., Wati, M.R. and Porter, A.G. 1998. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. *Journal of Biological Chemistry* 273: 9357-9360.
- Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. 2011. Global cancer statistics. *CA: A Cancer Journal for Clinicians* 61: 69-90.
- Jena, S., Dandapat, J. and Chainy, G.B.N. 2013. Curcumin differentially regulates the expression of superoxide dismutase in cerebral cortex and cerebellum of L-thyroxine (T4)-induced hyperthyroid rat brain. *Neurological Sciences* 34: 505-510.
- Ji, H.F., Li, X.J. and Zhang, H.Y. 2009. Natural products and drug discovery: Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? *European Molecular Biology Organization* 10: 194-200.
- Jokinen, E., Laurila, N. and Koivunen, J.P. 2012. Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. *BMC Cancer* 12: Article 612, 12 pages.
- Jordan, M.A. and Wilson, L. 2004. Microtubules as a target for anticancer drugs. *Nature Review Cancer* 4: 253-265.
- Joshi, A., Chaturvedi, S., Kumar, V. and Pathak, A. 2007. Phytosomes: A revolution in herbal drugs. *Pharmacological Reviews* 2: 11-13.
- Judd, N.P., Winkler, A.E., Murillo-Sauca, O., Brotman, J.J., Law, J.H., Lewis, J.S., Dunn, G.P., Bui, J.D., Sunwoo, J.B. and Uppaluri, R. 2012. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. *Cancer Research* 72: 365-374.
- Kagawa, S., Gu, J., Honda, T., McDonnell, T.J., Swisher, S.G., Roth, J.A. and Fang, B. 2001. Deficiency of caspase-3 in MCF7 cells blocks bax-mediated nuclear fragmentation but not cell death. *Clinical Cancer Research* 7: 1474-1480.
- Kamarudin, R., Shah, S.A. and Hidayah, N. 2006. Lifestyle factors and breast cancer: a case-control study in Kuala Lumpur, Malaysia. *Asian Pacific Journal of Cancer Prevention* 7: 51-54.
- Kaneda, N., Pezzuto, J.M., Kinghorn, A.D., Farnsworth, N.R., Santisuk, T., Tuchinda, P., Udchachon, J. and Reutrakul, V. 1992. Plant anticancer agents, L. cytotoxic triterpenes from *Sandoricum koetjape* stems. *Journal of Natural Products* 55: 654-659.
- Kang, K.S., Wang, P., Yamabe, N., Fukui, M., Jay, T. and Zhu, B.T. 2010. Docosahexaenoic acid induces apoptosis in MCF-7 cells *in vitro* and *in vivo* via reactive oxygen species formation and caspase 8 activation. *PLoS ONE* 5: e10296, 13 pages.

- Kannan, K. and Jain, S.K. 2000. Oxidative stress and apoptosis. *Pathophysiology* 7: 153-163.
- Kantari, C. and Walczak, H. 2011. Caspase-8 and Bid: Caught in the act between death receptors and mitochondria. *Biochimica et Biophysica Acta* 1813: 558-563.
- Karin, M., Yamamoto, Y. and Wang, Q.M. 2004. The IKK NF- κ B system: a treasure trove for drug development. *Nature Reviews Drug Discovery* 3: 17-26.
- Karl, S., Pritschow, Y., Volcic, M., Häcker, S., Baumann, B., Wiesmüller, L., Debatin, K.M. and Fulda, S. 2009. Identification of a novel pro-apoptotic function of NF- κ B in the DNA damage response. *Journal of Cellular and Molecular Medicine* 13: 4239-4256.
- Karlsson, P., Sun, Z., Braun, D., Price, K.N., Castiglione-Gertsch, M., Rabaglio, M., Gelber, R.D., Crivellari, D., Collins, J., Murray, E., Zaman, K., Colleoni, M., Gusterson, B.A., Viale, G., Regan, M.M., Coates, A.S. and Goldhirsch, A. 2011. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. *Annals of Oncology* 22: 2216-2226.
- Kasperczyk, H., La Ferla-Brühl, K., Westhoff, M.A., Behrend, L., Zwacka, R.M., Debatin, K.M. and Fulda, S. 2005. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. *Oncogene* 24: 6945-6956.
- Kensil, C.R. 1996. Saponins as vaccine adjuvants. *Critical Reviews in Therapeutic Drug Carrier Systems* 13: 1-55.
- Kerr, J.F.R., Wyllie, A.H. and Currie, A.R. 1972. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. *British Journal of Cancer* 26: 239-257.
- Kessler, J.H., Mullauer, F.B., de Roo, G.M. and Medema, J.P. 2007. Broad *in vitro* efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. *Cancer Letters* 251: 132-145.
- Kim, A.H., Khursigara, G., Sun, X., Franke, T.F. and Chao, M.V. 2001. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. *Molecular and Cellular Biology* 21: 893-901.
- Kim, C., Sano, Y., Todorova, K., Carlson, B.A., Arpa, L., Celada, A., Lawrence, T., Otsu, K., Brissette, J.L., Arthur, J.S. and Park, J.M. 2008. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. *Nature Immunology* 9: 1019-1027.
- Kitamura, T., Sekimata, M., Kikuchi, S. and Homma, Y. 2005. Involvement of poly(ADP-ribose) polymerase 1 in ERBB2 expression in rheumatoid synovial cells. *American Journal of Physiology-Cell Physiology* 289: C82-C88.

- Klaunig, J.E. and Kamendulis, L.M. 2004. The role of oxidative stress in carcinogenesis. *Annual Review of Pharmacology and Toxicology* 44: 239-267.
- Klaunig, J.E., Kamendulis, L.M. and Hocevar, B.A. 2010. Oxidative stress and oxidative damage in carcinogenesis. *Toxicologic Pathology* 38: 96-109.
- Kollmann, K., Heller, G. and Sexl, V. 2011. c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard. *Oncotarget* 2: 422-427.
- Komaki, R., Liao, Z.X., Cox, J.D., Mason, K.A. and Milas, L. 2011. Radioprotectors and chemoprotectors in the management of lung cancer. In *Advances in radiation oncology in lung cancer*, ed. B. Jeremic, pp. 223-246. Berlin: Springer.
- Kong, D.X., Li, X.J., Tang, G.Y. and Zhang, H.Y. 2008. How many traditional Chinese medicine components have been recognized by modern Western medicine? A chemoinformatic analysis and implications for finding multicomponent drugs. *ChemMedChem* 3: 233-236.
- Kowaltowski, A.J., Cosso, R.G., Campos, C.B. and Fiskum, G. 2002. Effect of Bcl-2 overexpression on mitochondrial structure and function. *Journal of Biological Chemistry* 277: 42802-42807.
- Kritikar, K.R. and Basu, B.D. 2003. Indian Medicinal Plants vol. 1. Dehradun: Oriental Enterprises.
- Krysko, D.V., Berghe, T.V., D'Herde, K. and Vandenabeele, P. 2008. Apoptosis and necrosis: Detection, discrimination and phagocytosis. *Methods* 44: 205-221.
- Kumar, D., Mallick, S., Vedasiromoni, J.R. and Pal, B.C. 2010. Anti-leukemic activity of *Dillenia indica* L. fruit extract and quantification of betulinic acid by HPLC. *Phytomedicine* 17: 431-435.
- Kumar, B., Koul, S., Khandrika, L., Meacham, R.B. and Koul, H.K. 2008. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. *Cancer Research* 68: 1777-1785.
- Kumar, S., Kumar, V. and Prakash, O. 2011. Antidiabetic, hypolipidemic and histopathological analysis of *Dillenia indica* (L.) leaves extract on alloxan induced diabetic rats. *Asian Pacific Journal of Tropical Medicine* 4: 347-352.
- Kumar, S. and Pandey, A.K. 2013. Chemistry and biological activities of flavonoids: An overview. *Scientific World Journal* 2013: Article ID 162750, 16 pages.
- Kundu, N., Zhang, S. and Fulton, A.M. 1995. Sublethal oxidative stress inhibits tumor cell adhesion and enhances experimental metastasis of murine mammary carcinoma. *Clinical and Experimental Metastasis* 13: 16-22.
- Kurian, A.W., Lichtensztajn, D.Y., Keegan, T.H.M., Nelson, D.O., Clarke, C.A. and Gomez, S.L. 2014. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. *Journal of the American Medical Association* 312: 902-914.

- Kuukasjärvi, T., Kononen, J., Helin, H., Holli, K. and Isola, J. 1996. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. *Journal of Clinical Oncology* 14: 2584-2589.
- Kyriakis, J.M. and Avruch, J. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. *Physiological Reviews* 81: 807-869.
- Lei, K. and Davis, R.J. 2003. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. *Proceedings of the National Academy of Sciences* 100: 2432-2437.
- Lee, J.A. and Cho, Y. 2008. Effect of ascorbic acid, silicon and iron on collagen synthesis in the human dermal fibroblast cell (HS27). *Journal of the Federation of American Societies for Experimental Biology* 22: 672.
- Lee, Y.K., Park, S.Y., Kim, Y.M., Lee, W.S. and Park, O.J. 2009. AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin. *Experimental and Molecular Medicine* 41: 201-207.
- Levenson, A.S. and Jordan, V.C. 1997. MCF-7: the first hormone-responsive breast cancer cell line. *Cancer Research* 57: 3071-3078.
- Li, X., Yang, G., Li, X., Zhang, Y., Yang, J., Chang, J., Sun, X., Zhou, X., Guo, Y., Xu, Y., Liu, J. and Bensoussan, A. 2013. Traditional Chinese medicine in cancer care: A review of controlled clinical studies published in Chinese. *PLoS ONE* 8: e60338, 11 pages.
- Li, Z.Y., Yang, Y., Ming, M. and Liu, B. 2011. Mitochondrial ROS generation for regulation of autophagic pathways in cancer. *Biochemical and Biophysical Research Communications* 414: 5-8.
- Liang, Y.Z., Xie, P. and Chan, K. 2004. Quality control of herbal medicines. *Journal of Chromatography B* 812: 53-70.
- Lin, L., Hutzen, B., Zuo, M., Ball, S., Deangelis, S., Foust, E., Pandit, B., Inhat, M.A., Shenoy, S.S., Kulp, S., Li, P.K., Li, C., Fuchs, J. and Lin, J. 2010. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. *Cancer Research* 70: 2445-2454.
- Lin, R. and Tripuraneni, P. 2011. Radiation therapy in early-stage invasive breast cancer. *Indian Journal of Surgical Oncology* 2: 101-111.
- Lind, M.J. 2008. Principles of cytotoxic chemotherapy. *Medicine* 36: 19-23.
- Liu, B., Han, M., Sun, R.H., Wang, J.J., Zhang, Y.P., Zhang, D.Q. and Wen, J.K. 2010. ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activation. *Breast Cancer Research* 12: Article R9, 15 pages.

- Liu, F., Bardhan, K., Yang, D., Thangaraju, M., Ganapathy, V., Waller, J.L., Liles, G.B., Lee, J.R. and Liu, K. 2012. NF- κ B directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. *Journal of Biological Chemistry* 287: 25530-25540.
- Liu, J.J., Lin, M., Yu, J.Y., Liu, B. and Bao, J.K. 2011. Targeting apoptotic and autophagic pathways for cancer therapeutics. *Cancer Letters* 300: 105-114.
- Liu, S.H. and Cheng, Y.C. 2012. Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy. *Journal of Ethnopharmacology* 140: 614-623.
- Liu, Y.B., Gao, X., Deeb, D., Arbab, A.S. and Gautam, S.C. 2013. Pristimerin induces apoptosis in prostate cancer cells by downregulating Bcl-2 through ROS-dependent ubiquitin-proteasomal degradation pathway. *Journal of Carcinogenesis and Mutagenesis* S6: Article 005, 20 pages.
- Liu, Z., Zhang, X.S. and Zhang, S. 2014. Breast tumor subgroups reveal diverse clinical prognostic power. *Scientific Reports* 4: Article ID 4002, 9 pages.
- Lobo, V., Patil, A., Phatak, A. and Chandra, N. 2010. Free radicals, antioxidants and functional foods: Impact on human health. *Pharmacognosy Review* 4: 118-126.
- Lontsi, D., Sondengam, B.L. and Ayafor, J.F. 1989. Chemical studies on the Cecropiaceae - A novel A-ring *seco*-triterpene from *Musanga cecropioides*. *Journal of Natural Products* 52: 52-56.
- Lontsi, D., Sondengam, B.L., Ayafor, J.F. and Connolly, J.D. 1987. Cecropiacic acid, a new pentacyclic A-ring *seco*-triterpenoid from *Musanga cecropioides*. *Tetrahedron Letters* 28: 6683-6686.
- Lontsi, D., Sondengam, B.L., Martin, M.T. and Bodo, B. 1991. *Seco*-ring-A-triterpenoids from the rootwood of *Musanga cecropioides*. *Phytochemistry* 30: 1621-1624.
- Lopez-Bergami, P., Huang, C., Goydos, J.S., Yip, D., Bar-Eli, M., Herlyn, M., Smalley, K.S., Mahale, A., Eroshkin, A., Aaronson, S. and Ronai, Z. 2007. Rewired ERK-JNK signaling pathways in melanoma. *Cancer Cell* 11: 447-460.
- Ma, X. and Wang, Z. 2009. Anticancer drug discovery in the future: An evolutionary perspective. *Drug Discovery Today* 14: 1136-1142.
- Macahig, R.A., Matsunami, K. and Otsuka, H. 2011. Chemical studies on an endemic Philippine plant: sulfated glucoside and *seco*-A-ring triterpenoids from *Dillenia philippinensis*. *Chemical and Pharmaceutical Bulletin* 59: 397-401.
- Macarron, R., Banks, M.N., Bojanic, D., Burns, D.J., Cirovic, D.A., Garyantes, T., Green, D.V.S., Hertzberg, R.P., Janzen, W.P., Paslay, J.W., Schopfer, U. and Sittampalam, G.S. 2011. Impact of high-throughput screening in biomedical research. *Nature Reviews Drug Discovery* 10: 188-195.

- Mahato, S.B. and Kundu, A.P. 1994. ^{13}C NMR spectra of pentacyclic triterpenoids - A compilation and some salient features. *Phytochemistry* 37: 1517-1575.
- Maioli, E., Greci, L., Soucek, K., Hyzdalova, M., Pecorelli, A., Fortino, V. and Valacchi, G. 2009. Rottlerin inhibits ROS formation and prevents NF κ B activation in MCF-7 and HT-29 cells. *Journal of Biomedicine and Biotechnology* 2009: Article ID 742936, 7 pages.
- Man, S., Gao, W., Zhang, Y., Huang, L. and Liu, C. 2010. Chemical study and medical application of saponins as anti-cancer agents. *Fitoterapia* 81: 703-714.
- Manchado, E., Guillaumot, M. and Malumbres, M. 2012. Killing cells by targeting mitosis. *Cell Death and Differentiation* 19: 369-377.
- Mandal, S.M., Chakraborty, D. and Dey, S. 2010. Phenolic acids act as signaling molecules in plant-microbe symbioses. *Plant Signaling and Behavior* 5: 359-368.
- Mander, M., Ntuli, L., Diederichs, N. and Mavundla, K. 2007. Economics of the traditional medicine trade in South Africa. *South African Health Review* 2007: 189-196.
- Marquette, C. and Nabell, L. 2012. Chemotherapy-resistant metastatic breast cancer. *Breast Cancer* 13: 263-275.
- Martin, F.T., Dwyer, R.M., Kelly, J., Khan, S., Murphy, J.M., Curran, C., Miller, N., Hennessy, E., Dockery, P., Barry, F.P., O'Brien, T. and Kerin, M.J. 2010. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). *Breast Cancer Research and Treatment* 124: 317-326.
- Martin, L.A., Farmer, I., Johnston, S.R.D., Ali, S., Marshall, C. and Dowsett, M. 2003. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. *Journal of Biological Chemistry* 278: 30458-30468.
- Massaoka, M.H., Matsuo, A.L., Figueiredo, C.R., Farias, C.F., Girola, N., Arruda, D.C., Scutti, J.A.B., Romoff, P., Favero, O.A., Ferreira, M.J.P., Lago, J.H.G. and Travassos, L.R. 2012. Jacaranone induces apoptosis in melanoma cells via ROS-mediated downregulation of Akt and p38 MAPK activation and displays antitumor activity *in vivo*. *PLoS ONE* 7: e38698, 11 pages.
- Mat Salleh, K. and Latiff, A. 2002. Tumbuhan Ubatan Malaysia. Bangi: Universiti Kebangsaan Malaysia.
- Maurya, D.K., Nandakumar, N. and Devasagayam, T.P. 2011. Anticancer property of gallic acid in A549, a human lung adenocarcinoma cell line, and possible mechanisms. *Journal of Clinical Biochemistry and Nutrition* 48: 85-90.
- Mego, M., Mani, S.A. and Cristofanilli, M. 2010. Molecular mechanisms of metastasis in breast cancer-clinical applications. *Nature Reviews Clinical Oncology* 7: 693-701.

- Meier, R., Rouse, J., Cuenda, A., Nebreda, A.R. and Cohen, P. 1996. Cellular stresses and cytokines activate multiple mitogen-activated-protein kinase kinase homologues in PC12 and KB cells. *European Journal of Biochemistry* 236: 796-805.
- Melzig, M.F., Bader, G. and Loose, R. 2001. Investigations of the mechanism of membrane activity of selected triterpenoid saponins. *Planta Medica* 67: 43-48.
- Mertens-Talcott, S.U., Bertoldi, M.C., Noratto, G.D. and Safe, S. 2012. Betulinic acid decreases ER-negative breast cancer cell growth *in vitro* and *in vivo*: Role of sp transcription factors and microRNA-27a:ZBTB10. *Molecular Carcinogenesis* 52: 591-602.
- Mizukami, Y., Yoshioka, K., Morimoto, S. and Yoshida, K. 1997. A novel mechanism of JNK1 activation: Nuclear translocation and activation of JNK1 during ischemia and reperfusion. *Journal of Biological Chemistry* 272: 16657-16662.
- Mohan, S., Abdelwahab, S.I., Kamalidehghan, B., Syam, S., May, K.S., Harmal, N.S.M., Shafifiyaz, N., Hadi, A.H.A., Hashim, N.M., Rahmani, M., Taha, M.M.E., Cheah, S.C. and Zajmi, A. 2012. Involvement of NF- κ B and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound Pyranocycloartobioxanthone A. *Phytomedicine* 19: 1007-1015.
- Moreno-Sanchez, R., Rodriguez-Enriquez, S., Marin-Hernandez, A. and Saavedra, E. 2007. Energy metabolism in tumor cells. *Federation of European Biochemical Societies Journal* 274: 1393-1418.
- Mosihuzzaman, M. and Choudhary, M.I. 2008. Protocols on safety, efficacy, standardization, and documentation of herbal medicine. *Pure and Applied Chemistry* 80: 2195-2230.
- Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *Journal of Immunological Methods* 65(1-2): 55-63.
- Mueller-Harvey, I. and McAllan, A.B. 1992. Tannins: Their biochemistry and nutritional properties. In *Advances in plant cell biochemistry and biotechnology*, ed. I.M. Morrison, pp. 151-217. London: JAI Press Ltd.
- Mukhopadhyay, K.D., Bandyopadhyay, A., Chang, T.A., Elkahloun, A.G., Cornell, J.E., Yang, J., Goins, B.A., Yeh, I.T. and Sun, L.Z. 2011. Isolation and characterization of a metastatic hybrid cell line generated by ER negative and ER positive breast cancer cells in mouse bone marrow. *PLoS ONE* 6: e20473, 11 pages.
- Muliawan, S.Y. 2008. Effect of *Dillenia suffruticosa* extract on dengue virus type 2 replication. *Universa Medicina* 27: 1-5.

- Murtaza, I., Saleem, M., Adhami, V.M., Hafeez, B.B. and Mukhtar, H. 2009. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. *Cancer Research* 69: 1156-1165.
- Musa, S.N. 2012. *In vitro* evaluation of antioxidant and cytotoxic properties of *Dillenia suffruticosa* extract, Bachelor Thesis, Universiti Putra Malaysia.
- Na, H.K., Kim, E.H., Choi, M.A., Park, J.M., Kim, D.H. and Surh, Y.J. 2012. Diallyl trisulfide induces apoptosis in human breast cancer cells through ROS-mediated activation of JNK and AP-1. *Biochemical Pharmacology* 84: 1241-1250.
- Nag, S.A., Qin, J.J., Wang, W., Wang, M.H., Wang, H. and Zhang, R. 2012. Ginsenosides as anticancer agents: *In vitro* and *in vivo* activities, structure-activity relationships, and molecular mechanisms of action. *Frontier in Pharmacology* 3: Article 25, 18 pages.
- Nakazato, T., Ito, K., Ikeda, Y. and Kizaki, M. 2005. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. *Clinical Cancer Research* 11: 6040-6049.
- Narang, A.S. and Desai, D.S. 2009. Anticancer drug development: Unique aspects of pharmaceutical development. In *Pharmaceutical Perspectives of Cancer Therapeutics*, ed. Y. Lu, and R.I. Mahato, pp. 49-92. New York: Springer.
- Nassirpour, R., Mehta, P.P., Baxi, S.M. and Yin, M.J. 2013. miR-221 promotes tumorigenesis in human triple negative breast cancer cells. *PLoS ONE* 8: e62170, 9 pages.
- National Cancer Institute 2014. Breast cancer. <http://www.cancer.gov/cancertopics/types/breast>. Retrieved 18th December 2014.
- Ng, W.K., Latifah, S.Y. and Ismail, M. 2011. Thymoquinone from *Nigella sativa* was more potent than cisplatin in eliminating of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. *Toxicology In Vitro* 25: 1392-1398.
- Nguyen-Pouplin, J., Tran, H., Tran, H., Phan, T.A., Dolecek, C., Farrar, J., Tran, T.H., Caron, P., Bodo, B. and Grellier, P. 2007. Antimalarial and cytotoxic activities of ethno-pharmacologically selected medicinal plants from South Vietnam. *Journal of Ethnopharmacology* 109: 417-427.
- Nick, A., Wright, A.D., Rali, T. and Sticher, O. 1995. Antibacterial triterpenoids from *Dillenia papuana* and their structure-activity relationships. *Pytochemistry* 40: 1691-1695.
- Nick, A., Wright, A.D., Sticher, O. and Rali, T. 1994. Antibacterial triterpenoid acids from *Dillenia papuana*. *Journal of Natural Products* 57: 1245-1250.

- Nigam, N., Prasad, S., George, J. and Shukla, Y. 2009. Lupeol induces p53 and cyclin-B-mediated G2/M arrest and targets apoptosis through activation of caspase in mouse skin. *Biochemical and Biophysical Research Communications* 381: 253-258.
- Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E. and Capaccioli, S. 2009. Review: Natural compounds for cancer treatment and prevention. *Pharmacological Research* 59: 365-378.
- Okouneva, T., Hill, B.T., Wilson, L. and Jordan, M.A. 2003. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. *Molecular Cancer Therapeutics* 2: 427-436.
- Omar, Z.A. and Nor Saleha, I.T. 2011. *National Cancer Registry Report 2007: Malaysia Cancer Statistics-Data and Figure*. Ministry of Health, Malaysia. National Cancer Registry: Putrajaya.
- Ouyang, L., Shi, Z., Zhao, S., Wang, F.T., Zhou, T.T., Liu, B. and Bao, J.K. 2012. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. *Cell Proliferation* 45: 487-498.
- Ozaki, T. and Nakagawara, A. 2011. Role of p53 in cell death and human cancers. *Cancers* 3: 994-1013.
- Pajaniradje, S., Mohankumar, K., Pamidimukkala, R., Subramanian, S. and Rajagopalan, R. 2014. Antiproliferative and apoptotic effects of *Sesbania grandiflora* leaves in human cancer cells. *BioMed Research International* 2014: Article ID 474953, 11 pages.
- Pan, S.Y., Zhou, S.F., Gao, S.H., Yu, Z.L., Zhang, S.F., Tang, M.K., Sun, J.N., Ma, D.L., Han, Y.F., Fong, W.F. and Ko, K.M. 2013. New perspectives on how to discover drugs from herbal medicines: CAM's outstanding contribution to modern therapeutics. *Evidence-Based Complementary and Alternative Medicine* 2013: Article ID 627375, 25 pages.
- Pandey, A. and Tripathi, S. 2014. Concept of standardization, extraction and pre phytochemical screening strategies for herbal drug. *Journal of Pharmacognosy and Phytochemistry* 2: 115-119.
- Park, E.H., Kim, Y.J., Yamabe, N., Park, S.H., Kim, H.K., Jang, H.J., Kim, J.H., Cheon, G.J., Ham, J. and Kang, K.S. 2014. Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. *Journal of Ginseng Research* 38: 22-27.
- Park, K.R., Nam, D., Yun, H.M., Lee, S.G., Jang, H.J., Sethi, G., Cho, S.K. and Ahn, K.S. 2011. β -Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation. *Cancer Letters* 312: 178-188.
- Patwardhan, B. 2014. Traditions, rituals and science of Ayurveda. *Journal of Ayurveda Integrative Medicine* 5: 131-133.

- Paul, S., Sengupta, S., Bandyopadhyay, T.K. and Bhattacharyya, A. 2012. Stevioside induced ROS-mediated apoptosis through mitochondrial pathway in human breast cancer cell line MCF-7. *Nutrition and Cancer* 64: 1087-1094.
- Pearcey, R., Brundage, M., Drouin, P., Jeffery, J., Johnston, D., Lukka, H., MacLean, G., Souhami, L., Stuart, G. and Tu, D. 2002. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. *Journal of Clinical Oncology* 20: 966-972.
- Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K. and Cobb, M.H. 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocrine Reviews* 22: 153-183.
- Peddi, P.F., Ellis, M.J. and Ma, C. 2012. Molecular basis of triple negative breast cancer and implications for therapy. *International Journal of Breast Cancer* 2012: Article ID 217185, 7 pages.
- Pei, J.S., Liu, C.C., Hsu, Y.N., Lin, L.L., Wang, S.C., Chung, J.G., Bau, D.T. and Lin, S.S. 2012. Amentoflavone induces cell-cycle arrest and apoptosis in MCF-7 human breast cancer cells via mitochondria-dependent pathway. *In Vivo* 26: 963-970.
- Pelicano, H., Carney, D. and Huang, P. 2004. ROS stress in cancer cells and therapeutic implications. *Drug Resistance Updates* 7: 97-110.
- Pelicano, H., Lu, W., Zhou, Y., Zhang, W., Chen, Z., Hu, Y. and Huang, P. 2009. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. *Cancer Research* 69: 2375-2383.
- Pelicano, H., Martin, D.S., Xu, R.H. and Huang, P. 2006. Glycolysis inhibition for anticancer treatment. *Oncogene* 25: 4633-4646.
- Peng, J. and Jordan, V.C. 2010. Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. *International Journal of Oncology* 36: 451-458.
- Perou, C.M., Sorlie, T., Eisen, M.B., Van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S.X., Lonning, P.E., Borresen-Dale, A.L., Brown, P.O. and Botstein, D. 2000. Molecular portraits of human breast tumours. *Nature* 406: 747-752.

- Phillips, K.A., Milne, R.L., Rookus, M.A., Daly, M.B., Antoniou, A.C., Peock, S., Frost, D., Easton, D.F., Ellis, S., Friedlander, M.L., Buys, S.S., Andrieu, N., Noguès, C., Stoppa-Lyonnet, D., Bonadona, V., Pujol, P., McLachlan, S.A., John, E.M., Hooning, M.J., Seynaeve, C., Tollenaar, R.A.E.M., Goldgar, D.E., Terry, M.B., Caldes, T., Weideman, P.C., Andrulis, I.L., Singer, C.F., Birch, K., Simard, J., Southey, M.C., Olsson, H.L., Jakubowska, A., Olah, E., Gerdes, A.M., Foretova, L. and Hopper, J.L. 2013. Tamoxifen and risk of contralateral breast cancer for *BRCA1* and *BRCA2* mutation carriers. *Journal of Clinical Oncology* 31: 1-11.
- Phillipson, J.D. 2003. Fifty years of medicinal plant research-every progress in methodology is a progress in science. *Planta Medica* 69: 491-495.
- Piccolo, M.T. and Crispi, S. 2012. The dual role played by p21 may influence the apoptotic or anti-apoptotic fate in cancer. *Journal of Cancer Research Updates* 1: 189-202.
- Pietkiewicz, J., Zielinska, K., Saczko, J., Kulbacka, J., Majkowski, M. and Wilk, K.A. 2010. New approach to hydrophobic cyanine-type photosensitizer delivery using polymeric oil-cored nanocarriers: hemolytic activity, *in vitro* cytotoxicity and localization in cancer cells. *European Journal of Pharmaceutical Sciences* 39: 322-335.
- Pisha, E., Chai, H., Lee, I.S., Chagwedera, T.E., Farnsworth, N.R., Cordell, G.A., Beecher, C.W., Fong, H.H., Kinghorn, A.D., Brown, D.M., Wani, M.C., Wall, M.E., Hieken, T.J., Gupta, T.K.D. and Pezzuto, J.M. 1995. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. *Nature Medicine* 1: 1046-1051.
- Poonam, K. and Singh, G.S. 2009. Ethnobotanical study of medicinal plants used by the Taungya community in Terai Arc Landscape, India. *Journal of Ethnopharmacology* 123: 167-176.
- Portt, L., Norman, G., Clapp, C., Greenwood, M. and Greenwood, M.T. 2011. Anti-apoptosis and cell survival: A review. *Biochimica et Biophysica Acta* 1813: 238-259.
- Prasad, P.R.C., Reddy, C.S. and Dutt, C.B.S. 2008. Folklore medicinal plants of North Andaman Islands, India. *Fitoterapia* 79: 458-464.
- Prasad, S., Yadav, V.R., Kannappan, R. and Aggarwal, B.B. 2011. Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. *Journal of Biological Chemistry* 286: 5546-5557.
- Proskuryakov, S.Y., Konoplyannikov, A.G. and Gabai, V.L. 2003. Necrosis: A specific form of programmed cell death? *Experimental Cell Research* 283: 1-16.
- Prousek, J. 2007. Fenton chemistry in biology and medicine. *Pure and Applied Chemistry* 79: 2325-2338.

- Purkayastha, J., Nath, S.C. and Islam, M. 2005. Ethnobotany of medicinal plants from Dibru-Saikhowa Biosphere Reserve of Northeast India. *Fitoterapia* 76: 121-127.
- Putcha, G.V., Le, S., Frank, S., Besirli, C.G., Clark, K., Chu, B., Alix, S., Youle, R.J., LaMarche, A., Maroney, A.C. and Johnson, E.M.J. 2003. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. *Neuron* 38: 899-914.
- Raaman, N. 2006. Phytochemical Techniques. New Delhi: New India Publishing Agency.
- Rai, V., Tandon, P.K. and Khatoon, S. 2014. Effect of chromium on antioxidant potential of *Catharanthus roseus* varieties and production of their anticancer alkaloids: Vincristine and vinblastine. *BioMed Research International* 2014: Article ID 934182, 10 pages.
- Raina, K., Rajamanickam, S., Deep, G., Singh, M., Agarwal, R. and Agarwal, C. 2008. Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. *Molecular Cancer Therapeutics* 7: 1258-1267.
- Rao, V., Krishna, J., Raja, G. and Badrinath, K.V.S. 2003. Notes on economic importance of wild plants of Rampa agency-East Godavari district, A.P., India. *Journal of Economic and Taxonomic Botany* 27: 603-612.
- Ray, L.B. and Sturgill, T.W. 1988. Insulin-stimulated microtubule-associated protein kinase is phosphorylated on tyrosine and threonine *in vivo*. *Proceedings of the National Academy of Sciences* 85: 3753-3757.
- Recio, J.A. and Merlino, G. 2002. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. *Oncogene* 21: 1000-1008.
- Reiner, T., Parrondo, R., Pozas, A.D.L., Palenzuela, D. and Perez-Stable, C. 2013. Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity. *PLoS ONE* 8: e56234, 11 pages.
- Ren, Z.F., Liu, W.S., Qin, H.D., Xu, Y.F., Yu, D.D., Feng, Q.S., Chen, L.Z., Shu, X.O., Zeng, Y.X. and Jia, W.H. 2010. Effect of family history of cancers and environmental factors on risk of nasopharyngeal carcinoma in Guangdong, China. *Cancer Epidemiology* 34: 419-424.
- Ring, A., Reed, M., Leonard, R., Kunkler, I., Muss, H., Wildiers, H., Fallowfield, L., Jones, A. and Coleman, R. 2011. The treatment of early breast cancer in women over the age of 70. *British Journal of Cancer* 105: 189-193.
- Romashkova, J.A. and Makarov, S.S. 1999. NF- κ B is a target of AKT in anti-apoptotic PDGF signalling. *Nature* 401: 86-90.
- Rosangkima, G. and Prasad, S.B. 2004. Antitumour activity of some plants from megalaya and Mizoram against murine ascites Dalton's lymphoma. *Indian Journal of Experimental Biology* 42: 981-988.

- Said, Z. 2010. *In vitro cytotoxicity and in vivo anti-neoplastic properties of Dillenia suffruticosa water extract on cervical carcinogenesis*, Master Thesis, Universiti Putra Malaysia.
- Saikia, A.P., Ryakala, V.K., Sharma, P., Goswami, P. and Bora, U. 2006. Ethnobotany of medicinal plants used by Assamese people for various skin ailments and cosmetics. *Journal of Ethnopharmacology* 106: 149-157.
- Saleem, M., Murtaza, I., Tarapore, R.S., Suh, Y., Adhami, V.M., Johnson, J.J., Siddiqui, I.A., Khan, N., Asim, M., Hafeez, B.B., Shekhani, M.T., Li, B. and Mukhtar, H. 2009. Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. *Carcinogenesis* 30: 808-817.
- Sarker, M.R. 2014. Therapeutic efficacy and safety of traditional Ayurvedic medicines: Demands for extensive research and publications. *Journal of Homeopathy and Ayurvedic Medicine* 3: e113, 2 pages.
- Schofield, P., Mbugua, D.M. and Pell, A.N. 2001. Analysis of condensed tannins: a review. *Animal Feed Science Technology* 91: 21-40.
- Schreiber, M., Kolbus, A., Piu, F., Szabowski, A., Möhle-Steinlein, U., Tian, J., Karin, M., Angel, P. and Wagner, E.F. 1999. Control of cell cycle progression by c-Jun is p53 dependent. *Genes and Development* 13: 607-619.
- Schwab, M., Claas, A. and Savelyeva, L. 2002. *BRCA2*: A genetic risk factor for breast cancer. *Cancer Letters* 175: 1-8.
- Selzer, E., Pimentel, E., Wacheck, V., Schlegel, W., Pehamberger, H., Jansen, B. and Kodym, R. 2000. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. *Journal of Investigative Dermatology* 114: 935-940.
- Shaffer, R., Tyldesley, S., Rolles, M., Chia, S. and Mohamed, I. 2009. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single-institution study. *Radiotherapy and Oncology* 90: 122-126.
- Shah, M. and Allegrucci, C. 2012. Keeping an open mind: highlights and controversies of the breast cancer stem cell theory. *Breast Cancer: Targets and Therapy* 4: 155-166.
- Shamas-Din, A., Brahmabhatt, H., Leber, B. and Andrews, D.W. 2011. BH3-only proteins: orchestrators of apoptosis. *Biochimica et Biophysica Acta* 1813: 508-520.
- Shankar, E., Krishnamurthy, S., Paranandi, R. and Basu, A. 2010. PKCepsilon induces Bcl-2 by activating CREB. *International Journal of Oncology* 36: 883-888.
- Sharma, H.K., Chhangte, L. and Dolui, A.K. 2001. Traditional medicinal plants in Mizoram, India. *Fitoterapia* 72: 146-161.

- Shearn, C.T., Reigan, P. and Petersen, D.R. 2012. Inhibition of hydrogen peroxide signaling by 4-hydroxynonenal due to differential regulation of Akt1 and Akt2 contributes to decreases in cell survival and proliferation in hepatocellular carcinoma cells. *Free Radical Biology and Medicine* 53: 1–11.
- Sheridan, C., Brumatti, G. and Martin, S.J. 2008. Oncogenic B-RAFV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. *Journal of Biological Chemistry* 283: 22128-22135.
- Shibata, M.A., Khan, I.A., Iinuma, M. and Shirai, T. 2012. Natural Products for Medicine. *Journal of Biomedicine and Biotechnology* 2012: Article ID 147120, 1 page.
- Siddiqi, A., Long, L.M., Li, L.X., Marciniak, R.A. and Kazhdan, I. 2008. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. *BMC Cancer* 8: Article 129, 8 pages.
- Sies, H. 1991. Oxidative stress: From basic research to clinical application. *American Journal of Medicine* 91: S31–S38.
- Silva, J.L., De Moura Gallo, C.V., Costa, D.C.F. and Rangel, L.P. 2014. Prion-like aggregation of mutant p53 in cancer. *Trends in Biochemical Sciences* 39: 260-267.
- Silva Júnior, J.O.C., Costa, R.M.R., Teixeira, F.M. and Barbosa, W.L.R. 2011. Processing and quality control of herbal drugs and their derivatives. In *Quality control of herbal medicines and related areas*, ed. Y. Shoyama, pp. 195-222. Croatia: InTech.
- Silver, D.P., Richardson, A.L., Eklund, A.C., Wang, Z.C., Szallasi, Z., Li, Q., Juul, N., Leong, C.O., Calogrias, D., Buraimoh, A., Fatima, A., Gelman, R.S., Ryan, P.D., Tung, N.M., De Nicolo, A., Ganesan, S., Miron, A., Colin, C., Sgroi, D.C., Ellisen, L.W., Winer, E.P. and Garber, J.E. 2010. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. *Journal of Clinical Oncology* 28: 1145-1153.
- Singh, B., Tai, K., Madan, S., Raythatha, M.R., Cady, A.M., Braunlin, M., Irving, L.R., Bajaj, A. and Lucci, A. 2012a. Selection of metastatic breast cancer cells based on adaptability of their metabolic state. *PLoS ONE* 7: e36510, 13 pages.
- Singh, N., Zaidi, D., Shyam, H., Sharma, R. and Balapure, A.K. 2012b. Polyphenols sensitization potentiates susceptibility of MCF-7 and MDA-MB-231 cells to centchroman. *PLoS ONE* 7: e37736, 14 pages.
- Singh, S. 2010. Global trade in herbal medicines: An Indian perspective. Saarbrücken: VDM Verlag Dr. Müller.

- Smith, L.D., Tesoriero, A.A., Ramus, S.J., Dite, G., Royce, S.G., Giles, G.G., McCredie, M.R.E., Hopper, J.L. and Southey, M.C. 2007. *BRCA1* promoter deletions in young women with breast cancer and a strong family history: A population-based study. *European Journal of Cancer* 43: 823-827.
- Șoica, C.M., Dehelean, C.A., Peev, C., Aluas, M., Zupkó, I., Kása, P.J. and Alexa, E. 2012. Physico-chemical comparison of betulinic acid, betulin and birch bark extract and *in vitro* investigation of their cytotoxic effects towards skin epidermoid carcinoma (A431), breast carcinoma (MCF7) and cervix adenocarcinoma (HeLa) cell lines. *Natural Product Research* 26: 968-974.
- Sood, S.K., Bhardwaj, R. and Lakhanpal, T.N. 2005. *Ethnic Indian Plants in Cure of Diabetes*. Jodhpur: Scientific Publishers.
- Sørli, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., Van de Rijn, M., Jeffrey, S.S., Thorsen, T., Quist, H., Matese, J.C., Brown, P.O., Botstein, D., Lønning, P.E. and Børresen-Dale, A.L. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proceedings of the National Academy of Sciences* 98: 10869-10874.
- Soule, H.D., Vazquez, J., Long, A., Albert, S. and Brennan, M. 1973. A human cell line from a pleural effusion derived from a breast carcinoma. *Journal of the National Cancer Institute* 51: 1409-1416.
- Spitale, A., Mazzola, P., Soldini, D., Mazzucchelli, L. and Bordoni, A. 2009. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. *Annals of Oncology* 20: 628-635.
- Srithi, K., Balslev, H., Wangpakattananawong, P., Srisanga, P. and Trisonthi, C. 2009. Medicinal plant knowledge and its erosion among the Mien (Yao) in Northern Thailand. *Journal of Ethnopharmacology* 123: 335-342.
- Srivastava, S.D. 1981. Flavonoids from the stem of *Dillenia pentagyna*. *Phytochemistry* 20: 2445.
- Stein, B., Brady, H., Yang, M.X., Young, D.B. and Barbosa, M.S. 1996. Cloning and characterization of MEK6, a novel member of the mitogenactivated protein kinase cascade. *Journal of Biological Chemistry* 271: 11427-11433.
- Su, C.L., Huang, L.L., Huang, L.M., Lee, J.C., Lin, C.N. and Won, S.J. 2006. Caspase-8 acts as a key upstream executor of mitochondria during justicidin A-induced apoptosis in human hepatoma cells. *FEBS Letters* 580: 3185-3191.
- Subik, K., Lee, J.F., Baxter, L., Strzepek, T., Costello, D., Crowley, P., Xing, L.P., Hung, M.C., Bonfiglio, T., Hicks, D.G. and Tang, P. 2010. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. *Breast Cancer* 4: 35-41.

- Subramani, T., Yeap, S.K., Ho, W.Y., Ho, C.L., Omar, A.R., Aziz, S.A., Nik Abd. Rahman, N.M.A. and Alitheen, N.B. 2013. Vitamin C suppresses cell death in MCF-7 human breast cancer cells induced by tamoxifen. *Journal of Cellular and Molecular Medicine* 18: 305-313.
- Sun, Y.F., Song, C.K., Viernstein, H., Unger, F. and Liang, Z.S. 2013. Apoptosis of human breast cancer cells induced by microencapsulated betulinic acid from sour jujube fruits through the mitochondria transduction pathway. *Food Chemistry* 138: 1998-2007.
- Szanto, A., Bogнар, Z., Szigeti, A., Szabo, A., Farkas, L. and Gallyas, F.J. 2009. Critical role of Bad phosphorylation by Akt in cytosolic resistance of human bladder cancer cells. *Anticancer Research* 29: 159-164.
- Tadesse, G., Reneela, P. and Dekebo, A. 2012. Isolation and characterization of natural products from *Helinus mystachus* (Rhamnaceae). *Journal of Chemical and Pharmaceutical Research* 4: 1756-1762.
- Taib, N.A., Yip, C.H., Ibrahim, M., Ng, C.J. and Farizah, H. 2007. Breast cancer in Malaysia: Are our women getting the right message? 10 year-experience in a single institution in Malaysia. *Asian Pacific Journal of Cancer Prevention* 8: 141-145.
- Takai, N., Ueda, T., Nishida, M., Nasu, K. and Narahara, H. 2008. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. *International Journal of Molecular Medicine* 21: 637-643.
- Tan, Y., Yu, R. and Pezzuto, J.M. 2003. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. *Clinical Cancer Research* 9: 2866-2875.
- Tarak, D., Namsa, N.D., Tangjang, S., Arya, S.C., Rajbonshi, B., Samal, P.K. and Mandal, M. 2011. An inventory of the ethnobotanicals used as anti-diabetic by a rural community of Dhemaji district of Assam, Northeast India. *Journal of Ethnopharmacology* 138: 345-350.
- Taylor, W.R. and Grabovich, A. 2009. Targeting the cell cycle to kill cancer cells. In *Pharmacology: Principles and Practice*, ed. M.P. Hacker, W.S. Messer, and K.A. Bachmann, pp. 429-453. California: Academic Press.
- Thornton, T.M. and Rincon, M. 2009. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. *International Journal of Biological Sciences* 5: 44-51.
- Thurnher, D., Turhani, D., Pelzmann, M., Wannemacher, B., Knerer, B., Formanek, M., Wacheck, V. and Selzer, E. 2003. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. *Head and Neck* 25: 732-740.
- Timur, M., Akbas, S.H. and Ozben, T. 2005. The effect of topotecan on oxidative stress in MCF-7 human breast cancer cell line. *Acta Biochimica Polonica* 52: 897-902.

- Tiwari, K.P., Srivastava, S.D. and Srivastava, S.K. 1980. A-l-rhamnopyranosyl-3/3-hydroxy-lup-20(29)-en-28-oic acid from the stem of *Dillenia pentagyna*. *Phytochemistry* 19: 980-981.
- Tiway, R., Yu, W., Li, J., Park, S.K., Sanders, B.G. and Kline, K. 2010. Role of endoplasmic reticulum stress in α -TEA mediated TRAIL/DR5 death receptor dependent apoptosis. *PLoS ONE* 5: e11865, 10 pages.
- Tommasi, S., Crapolicchio, A., Lacalamita, R., Bruno, M., Monaco, A., Petroni, S., Schittulli, F., Longo, S., Digennaro, M., Calistri, D., Mangia, A. and Paradiso, A. 2005. *BRCA1* mutations and polymorphisms in a hospital based consecutive series of breast cancer patients from Apulia, Italy. *Mutation Research* 57: 395-405.
- Tor, Y.S., Latifah, S.Y., Foo, J.B., Armania, N., Cheah, Y.K., Abdullah, R., Imam, M.U., Ismail, N. and Ismail, M. 2014. Induction of apoptosis through oxidative stress-related pathways in MCF-7, human breast cancer cells, by ethyl acetate extract of *Dillenia suffruticosa*. *BMC Complementary and Alternative Medicine* 14: Article 55, 12 pages.
- Trachootham, D., Alexandre, J. and Huang, P. 2009. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? *Nature Reviews Drug Discovery* 8: 579-591.
- Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P.J., Achanta, G., Arlinghaus, R.B., Liu, J. and Huang, P. 2006. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. *Cancer Cell* 10: 241-252.
- Tran, M.A., Smith, C.D., Kester, M. and Robertson, G.P. 2008. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. *Clinical Cancer Research* 14: 3571-3581.
- Tran, S.E., Holmstrom, T.H., Ahonen, M., Kahari, V.M. and Eriksson, J.E. 2001. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. *Journal of Biological Chemistry* 276: 16484-16490.
- Tulchin, N., Chambon, M., Juan, G., Dikman, S., Strauchen, J., Ornstein, L., Billack, B., Woods, N.T. and Monteiro, A.N. 2010. BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines. *American Journal of Pathology* 176: 1203-1214.
- Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., Wardley, A., Mitchell, G., Earl, H., Wickens, M. and Carmichael, J. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and advanced breast cancer: a proof-of-concept trial. *Lancet* 376: 235-244.
- Tyler, V.E. 1999. Phytomedicines: back to the future. *Journal of Natural Products* 62: 1589-1592.

- Vaidya, A.D.B. and Devasagayam, T.P.A. 2007. Current status of herbal drugs in India: An overview. *Journal of Clinical Biochemistry and Nutrition* 41: 1-11.
- Van Antwerp, D.J., Martin, S.J., Kafri, T., Green, D.R. and Verma, I.M. 1996. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. *Science* 274: 787-789.
- Van Cruchten, S. and Van Den Broeck, W. 2002. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. *Anatomia, Histologia, Embryologia* 31: 214-223.
- Van de Rijn, M., Perou, C.M., Tibshirani, R., Haas, P., Kallioniemi, O., Kononen, J., Torhorst, J., Sauter, G., Zuber, M., Kochli, O.R., Mross, F., Dieterich, H., Seitz, R., Ross, D., Botstein, D. and Brown, P. 2002. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. *American Journal of Pathology* 161: 1991-1996.
- Verhoven, B., Schlegel, R.A. and Williamson, P. 1995. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. *Journal of Experimental Medicine* 182: 1597-1601.
- Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., Fang, L., Lu, M.W., Olsen, S. and Blackwell, K. 2012. Trastuzumab emtansine for HER2-positive advanced breast cancer. *New England Journal of Medicine* 367: 1783-1791.
- Verpoorte, R. 2012. Good practices: The basis for evidence-based medicines. *Journal of Ethnopharmacology* 140: 455-457.
- Viale, G., Regan, M.M., Maiorano, E., Mastropasqua, M.G., Golouh, R., Perin, T., Brown, R.W., Kovács, A., Pillay, K., Hilschlegel, C., Bray, S., Grigolato, P., Rusca, T., Gelber, R.D., Castiglione-Gertsch, M., Price, K.N., Goldhirsch, A., Gusterson, B.A. and Coates, A.S. 2008. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. *Journal of Clinical Oncology* 26: 1404-1410.
- Vincken, J.P., Heng, L., de Groot, A. and Gruppen, H. 2007. Saponins, classification and occurrence in the plant kingdom. *Phytochemistry* 68: 275-297.
- Vousden, K.H. and Prives, C. 2009. Blinded by the light: the growing complexity of p53. *Cell* 137: 413-431.
- Wagner, E.F. and Nebreda, Á.R. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. *Nature Reviews Cancer* 9: 537-549.
- Walton, N.J., Mayer, M.J. and Narbad, A. 2003. Molecules of Interest: Vanillin. *Phytochemistry* 63: 505-515.

- Wang, Z., Zhang, H., Xu, X., Shi, H., Yu, X., Wang, X., Yan, Y., Fu, X., Hu, H., Li, X. and Xiao, J. 2012. bFGF inhibits ER stress induced by ischemic oxidative injury via activation of the PI3K/Akt and ERK1/2 pathways. *Toxicology Letters* 212: 137-146.
- Wang, Z.G. and Ren, J. 2002. Current status and future direction of Chinese herbal medicine. *Trends in Pharmacological Sciences* 23: 347-348.
- Watson, J. 2013. Oxidants, antioxidants and the current incurability of metastatic cancers. *Open Biology* 3: e120144, 9 pages.
- Weber, P., Bendich, A. and Schalch, W. 1996. Vitamin C and human health-A review of recent data relevant of human requirements. *International Journal for Vitamin and Nutrition Research* 66: 19-22.
- Wei, Y.Y., Chen, Y.J., Hsiao, Y.C., Huang, Y.C., Lai, T.H. and Tang, C.H. 2008. Osteoblasts-derived TGF- β 1 enhance motility and integrin upregulation through Akt, ERK, and NF- κ B-dependent pathway in human breast cancer cells. *Molecular Carcinogenesis* 47: 526-537.
- Welshons, W.V., Wolf, M.F., Murphy, C.S. and Jordan, V.C. 1988. Estrogenic activity of phenol red. *Molecular and Cellular Endocrinology* 57: 169-178.
- Weston, C.R. and Davis, R.J. 2002. The JNK signal transduction pathway. *Current Opinion in Genetics & Development* 12: 14-21.
- WHO 2002. WHO Traditional Medicine Strategy 2002-2005. Geneva: World Health Organisation.
- WHO 2012a. Regional progress in traditional medicine 2011-2010. http://www.wpro.who.int/traditional_medicine/data/en/. Retrieved 16th July 2014.
- WHO 2012b. WHO launches the first global strategy on traditional and alternative medicine. <http://www.who.int/mediacentre/news/releases/release38/en/>. Retrieved 1st October 2014.
- Wiat, C., Mogana, S., Khalifah, S., Mahan, M., Ismail, S., Buckle, M., Narayana, A.K. and Sulaiman, M. 2004. Antimicrobial screening of plants used for traditional medicine in the state of Perak, Peninsular Malaysia. *Fitoterapia* 75: 68-73.
- Wibowo, A., Ahmat, N., Hamzah, A.S., Low, A.L., Mohamad, S.A., Khong, H.Y., Sufian, A.S., Manshoor, N. and Takayama, H. 2012. Malaysianol B, an oligostilbenoid derivative from *Dryobalanops lanceolata*. *Fitoterapia* 83: 1569-1575.
- Wibowo, A., Ahmat, N., Hamzah, A.S., Sufian, A.S., Ismail, N.H., Ahmad, R., Jaafar, F.M. and Takayama, H. 2011. Malaysianol A, a new trimer resveratrol oligomer from the stem bark of *Dryobalanops aromatica*. *Fitoterapia* 82: 676-681.

- Wick, W., Grimmel, C., Wagenknecht, B., Dichgans, J. and Weller, M. 1999. Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. *Journal of Pharmacology and Experimental Therapeutics* 289: 1306-1312.
- Wisdom, R., Johnson, R.S. and Moore, C. 1999. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. *EMBO Journal* 18: 188-197.
- Wong, K.K., Fracasso, P.M., Bukowski, R.M., Lynch, T.J., Munster, P.N., Shapiro, G.I., Jänne, P.A., Eder, J.P., Naughton, M.J., Ellis, M.J., Jones, S.F., Mekhail, T., Zacharchuk, C., Vermette, J., Abbas, R., Quinn, S., Powell, C. and Burris, H.A. 2009. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. *Clinical Cancer Research* 15: 2552-2558.
- Wu, G., Qian, Z., Guo, J., Hu, D., Bao, J., Xie, J., Xu, W., Lu, J., Chen, X. and Wang, Y. 2012. *Ganoderma lucidum* extract induces G₁ cell cycle arrest, and apoptosis in human breast cancer cells. *American Journal of Chinese Medicine* 40: 631-642.
- Wu, W.S. 2006. The signaling mechanism of ROS in tumor progression. *Cancer Metastasis Review* 25: 695-705.
- Wu, X.Y., Tang, J.L., Mao, C., Yuan, J.Q., Qin, Y. and Chung, V.C.H. 2013. Systematic reviews and meta-analyses of traditional Chinese medicine must search Chinese databases to reduce language bias. *Evidence-Based Complementary and Alternative Medicine* 2013: Article ID 812179, 7 pages.
- Wysowski, D.K., Honig, S.F. and Beitz, J. 2002. Uterine sarcoma is associated with tamoxifen use. *New England Journal of Medicine* 346: 1832-1833.
- Xia, M., Knezevic, D. and Vassilev, L.T. 2011. p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation. *Oncogene* 30: 346-355.
- Xiao, D., Powolny, A.A. and Singh, S.V. 2008a. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. *Journal of Biological Chemistry* 283: 30151-30163.
- Xiao, D., Vogel, V. and Singh, S.V. 2006. Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak. *Molecular Cancer Therapeutics* 5: 2931-2945.
- Xiao, D., Zeng, Y., Prakash, L., Badmaev, V., Majeed, M. and Singh, S.V. 2011. Reactive oxygen species-dependent apoptosis by gugalipid extract of Ayurvedic medicine plant *Commiphora mukul* in human prostate cancer cells is regulated by c-Jun N-terminal kinase. *Molecular Pharmacology* 79: 499-507.
- Xiao, Y., Li, X., Yang, Y., Wang, Y. and Rao, S. 2008b. Cell cycle-dependent gene networks relevant to cancer. *Progress in Natural Science* 18: 945-952.

- Xuan, H., Li, Z., Yan, H., Sang, Q., Wang, K., He, Q., Wang, Y. and Hu, F. 2014. Antitumor activity of Chinese propolis in human breast cancer MCF-7 and MDA-MB-231 cells. *Evidence-Based Complementary and Alternative Medicine* 2014: Article ID 280120, 11 pages.
- Yanamadala, V., Negoro, H., Gunaratnam, L., Kong, T. and Denker, B.M. 2007. Galphal2 stimulates apoptosis in epithelial cells through JNK1-mediated Bcl-2 degradation and up-regulation of IkappaBalpha. *Journal of Biological Chemistry* 282: 24352-24363.
- Yang, C.S. and Wang, Z.Y. 1993. Tea and cancer (review). *Journal of the National Cancer Institute* 85: 1038-1049.
- Yang, C.W., Lee, Y.Z., Hsu, H.Y., Wu, C.M., Chang, H.Y., Chao, Y.S. and Lee, S.J. 2013. c-Jun-mediated anticancer mechanisms of tylophorine. *Carcinogenesis* 34: 1304-1314.
- Yang, Z.Z., Tschoop, O., Baudry, A., Dümmler, B., Hynx, D. and Hemmings, B.A. 2004. Physiological functions of protein kinase B/Akt. *Biochemical Society Transactions* 32: 350-354.
- Ye, Y., Xiao, Y., Wang, W., Yearsley, K., Gao, J.X., Shetuni, B. and Barsky, S.H. 2010. ERalpha signaling through slug regulates E-cadherin and EMT. *Oncogene* 29: 1451-1462.
- Yeshwante, S.B., Juvekar, A.R., Nagmoti, D.M., Wnakhede, S.S., Shah, A.S. and Pimprikar, R.B. 2009. Anti-inflammatory activity of methanolic extracts of *Dillenia indica* L. leaves. *Journal of Young Pharmacist* 1 1: 63-66.
- Yip, C.H., Taib, N.A. and Mohamed, I. 2006. Epidemiology of breast cancer in Malaysia. *Asian Pacific Journal of Cancer Prevention* 7: 369-374.
- Yu, T.W., Bai, L., Clade, D., Hoffmann, D., Toelzer, S., Trinh, K.Q., Xu, J., Moss, S.J., Leistner, E. and Floss, H.G. 2002. The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from *Actinosynnema pretiosum*. *Proceedings of the National Academy of Sciences* 99: 7968-7973.
- Zhang, Y.X., Kong, C.Z., Wang, L.H., Li, J.Y., Liu, X.K., Xu, B., Xu, C.L. and Sun, Y.H. 2010. Ursolic acid overcomes Bcl-2-mediated resistance to apoptosis in prostate cancer cells involving activation of JNK-induced Bcl-2 phosphorylation and degradation. *Journal of Cellular Biochemistry* 109: 764-773.
- Zhang, Z.W., Abdullahi, M. and Farthing, M.J.G. 2002. Effect of physiological concentrations of vitamin C on gastric cancer cells and *Helicobacter pylori*. *Gut* 50: 165-169.
- Zong, W.X., Ditsworth, D., Bauer, D.E., Wang, Z.Q. and Thompson, C.B. 2004. Alkylating DNA damage stimulates a regulated form of necrotic cell death. *Genes and Development* 18: 1272-1282.

Zuco, V., Supino, R., Righetti, S.C., Cleris, L., Marchesi, E., Gambacorti-Passerini, C. and Formelli, F. 2002. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. *Cancer Letters* 175: 17-25.

